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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
 
 
 
 
 
 
 
 
 
 
 
 
Steering Group of the evaluation 
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Panel members 
CHAIR 
Professor Lorenz Poellinger 
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Karolinska Institute, Sweden 
 
VICE-CHAIR 
Professor Cornelia van Duijn 
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The panel, independently, evaluated all the submitted material and was responsible for the 
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discussion and report writing. 
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Finland 
 
Professor Anders Linde 
Oral biochemi 
Faculty of Odontology 
Göteborg University 
Sweden 
 
 
2 
 
Experts from the Other Panels 
Professor Jan-Otto Carlsson, from the Panel of Natural Sciences 
Professor Danny Huylebroek, from the Panel of Biological, Agricultural and Veterinary 
Sciences 
Professor Holger Stark, from the Panel of Natural Sciences 
 
 
 
 
 
EVALUATION OFFICE 
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Mrs Aija Kaitera, Project Manager of TUHAT-RIS served the project ex officio 
providing the evaluation project with the updated information from TUHAT-RIS. 
The TUHAT office assisted in mapping the publications with CWTS/University of 
Leiden. 
MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
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Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
  
4 
 
 
  
 
 
5 
 
1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
The RC CANBIO is composed of 18 research groups working at Meilahti and Viikki campuses. The RC 
combines different aspects of cancer research ranging from basic research to translational research, 
diagnostics and clinical research. The RC includes some of the most prominent and internationally 
recognized names of Finnish medical research. Seven of the PIs are members of Finnish Centres of 
Excellence (2006-2011 CoE in Cancer Biology: Alitalo, Keski-Oja, Laiho, Salven; and CoE in Translational 
Genome-Scale Biology: Kallioniemi, Mäkelä, Ojala). Two PIs are professors of the Academy of Finland 
(Alitalo, Joensuu), and additional two are research directors of national research institutes (Institute for 
Molecular Medicine Finland (FIMM), Director Kallioniemi; Institute of Biotechnology, Director Mäkela). In 
addition, core facilities such as the high-throughput services in FIMM (Kallioniemi), the Biomedicum 
Genomics Center (Klefström, Monni), the Biocenter Finland Genome-Wide Methods Network (Mäkelä) and 
the Biomedicum Imaging Unit (Co-director Laiho) are directed by principal investigators of CANBIO. Thus, 
key strengths of the RC are proven scientific excellence, a complementary combination of different 
aspects of cancer research and in depth knowledge of cutting edge research technologies. 
The scientific quality of CANBIO is outstanding by international standards. Most of the RC’s groups 
have published their results in prime journals, including Journal of Cell Biology, Journal of Clinical 
Oncology, Cancer Research, New England Journal of Medicine, Circulation Research, Proceedings of the 
National Academy of Sciences of the United States of America, EMBO Journal, Nature Genetics, Cancer 
Cell, Nature Cell Biology, Lancet Oncology, and Nature Methods. The RC has made important novel 
contributions in the fields of angiogenesis, cell-cell and cell-matrix interactions, DNA damage control, 
genetic basis of cancer etc., it has developed novel methods for cancer research and it has been active in 
clinical trials on cancer drugs, some of which have modified the existing treatment protocols. 
The overall concept of CANBIO reflects the modern trends of cancer research, in which cutting edge 
research requires multiple approaches and a variety of sophisticated technologies. There is little overlap in 
the research focus of the different groups, rather the combination provides added value to research. 
Numeric evaluation: 5 (Outstanding) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
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 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
CANBIO has trained 15 doctoral students during the years 2005-2010, which is a rather low number for 18 
research groups. Importantly, many of the students have continued their career in established 
international research groups. Recruitment appears to be organized by individual research groups and 
funding comes partly from two doctoral programs, MD/PhD program (Faculty of Medicine) and Helsinki 
Biomedical Graduate School, the latter of which has been coordinated at various periods by CANBIO 
group leaders (Keski-Oja, Mäkelä, Ojala). From 2010 on, the FIMM-affiliated groups have been part of 
Nordic EMBL Graduate School, which recruited two doctoral students from FIMM in the year 2010. 
Training is organized mostly by the graduate schools. It is not quite clear, how established and formal 
training collaboration exists between the research groups within CANBIO. An area of development could 
be a structured PhD program, which would take into account the versatility of the RC groups and provide 
the trainees with different methodologies and approaches to cancer studies. 
Numeric evaluation: 4 (Excellent) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The societal impact does not only come from research results, which for the main part has indirect or 
even direct implication for cancer patients. The CANBIO members are very prominent in promoting 
research and translating results to the general audience, and participating in academic activities, such as 
committees, councils and boards. The members are also involved in organizing university infrastructure, 
and in science policy making. CANBIO has also well established connections to the private sector. 
Numeric evaluation: 5 (Outstanding) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The CANBIO RC is linked to several national and international research networks. Apart from the Academy 
of Finland Centres of Excellence, the members are associated with four Biocenter Finland merging 
Infrastructure Consortia: Genetically engineered mouse models, Viral gene transfer and cell therapy, 
Genome-wide methods and Translational technologies platform. The RC groups are also active in 
international collaborations, as exemplified by EU FP7 consortium GENICA and Innovative Medicines 
Initiative (IMI). The FIMM-affiliated groups are part of Nordic EMBL Graduate School. 
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Although most PIs are of Finnish origin, two junior PIs (Kuznetsov and Verschuren) were recently 
recruited from US and over 40 PhD students or post-docs are of foreign nationality, which clearly exceeds 
the national average of foreign investigators. 
Numeric evaluation: 5 (Outstanding) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
It is quite clear that the RC is very active in providing infrastructure (including core facilities) to the 
biomedical research community at the University of Helsinki. Other than that, the RC has access and 
actively uses major infrastructure at the Meilahti and Viikki biomedical campus. When considering 
translational and clinical cancer research, the RC might better utilize the close connections with the largest 
University hospital in Finland in order to improve the transition of their seminal findings to the clinic. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
The RC member groups are affiliated with different organizational structures: two research programs of 
the Faculty of Medicine, with faculty departments, with the Institute of Biotechnology or with the Institute 
of Molecular Medicine (FIMM). It appears that leadership and management is primarily organized via host 
institutes, and the RC is rather a loose academic consortium with unofficial structure. In spite of this, the 
RC has succeeded well in fostering successful collaborative research. It is unlikely that another level of 
organizational structure would provide significant benefit, rather it would just increase bureaucracy. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
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2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The RC has collected almost 19 Mill € of external funding during the period, of which over 5.5 Mill € is 
international funding. These values are excellent and indicate the high quality of research within the RC. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The RC plans to adopt several new cutting-edge technologies to foster cancer research. Especially 
techniques related to genomics, genome-scale and chemical biology and bioinformatics will be employed. 
The use of fresh tissue material for in vitro tests and genomic and epigenomic analyses will be increased. 
Biomarker identification and validation with the aid of biobank material will be a priority. All these 
advances will undoubtedly close the gap between basic science and patient care. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 1. The research of the participating community represents the international cutting edge in its field. 
 
The CANBIO RC clearly fits within the chosen participation category 1. 
Numeric evaluation: 5 (Outstanding) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
All research groups of the RC have contributed to the evaluation material, and the tasks seem to be 
distributed in a fair and productive way. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 6: Clinical research 
 
The research of CANBIO falls into the focus area: “health and welfare”, and within several of the key focus 
areas: ‘The basic structure of life’ (systemic biology and biotechnology) and ‘Clinical research’ (clinical 
translational medicine, personalized medicine). 
2.12 RC-specific main recommendations 
— 
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2.13 RC-specific conclusions 
— 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
 
 
 
 
 
International evaluation of research and doctoral training 
at the University of Helsinki 2005-2010 
 
         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Genome-Scale Cancer Biology (CANBIO) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Academy Professor Kari Alitalo, Research Programs Unit, Faculty of medicine 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Alitalo, Kari 
E-mail:  
Phone: 09 191 25511 
Affiliation: Faculty of Medicine, Resereach Programs Unit, Molecular Cancer Biology Group 
Street address: Haartmaninkatu 8 
 
 
Name of the participating RC (max. 30 characters): Genome-Scale Cancer Biology 
Acronym for the participating RC (max. 10 characters): CANBIO 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): The Genome-Scale Cancer 
Biology Research Consortium is formed by 15 active research groups in the University of Helsinki focusing 
on different aspects of cancer biology. The participating groups include established groups led by 
Professors and an Academy Professor, more junior research groups as well as recently established research 
laboratories, which are in a growing phase. This consortium brings together PIs with diverse backgrounds in 
medicine, biochemistry, genetics, virology, as well as cell and molecular biology. The methods and 
approaches used by the participating groups cover a wide field of cutting edge technologies from mouse 
molecular genetics to signal transduction and cell biology, from clinical cancer research to high-throughput 
approaches and viral technologies. 
The driving force for the formation of the CANBIO research consortium is the existing and extensive 
collaboration between the groups, which is in many cases based on the combination of complementing 
technological and scientific know-how of the research groups. In addition, technological facilities such as 
the high-throughput services in FIMM (Kallioniemi), Biomedicum Genomics (Monni, Klefström), the 
Biocenter Finland Genome-Wide Methods Network (Mäkela) and the Biomedicum Imaging Unit (Laiho Co-
director), are directed by PIs of the CANBIO consortium, as indicated in the parenthesis. The collaboration is 
perhaps best exemplified in joint publications in high-profile journals.  
However, the consortium also maintains an intense exchange of knowledge among the participating labs by 
providing methodological and scientific expertise and e.g. by providing opportunities of the doctoral 
students to learn new techniques via laboratory visits, which may not lead to joint publications. This change 
of information is straightforward and very informal between the laboratories, and occurs frequently. 
Due to close research interests, many of the CANBIO PIs also serve as mentors or thesis committee 
members for doctoral students from other participating research groups, thus contributing to the doctoral 
thesis work performed within the consortium. 
 
 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Oncology 
RC's scientific subfield 2: Biochemistry and Molecular Biology 
RC's scientific subfield 3: Genetics and Heredity 
RC's scientific subfield 4: Cell Biology 
Other, if not in the list:  
 
 
Participation category: 1. Research of the participating community represents the international cutting 
edge in its field 
Justification for the selected participation category (MAX. 2200 characters with spaces):  Researchers in 
the CANBIO Research Consortium perform at the leading edge of Finnish cancer biology basic research 
(notably Prof. Kari Alitalo) and clinical cancer biology research fields (notably Prof. Heikki Joensuu). The 
CANBIO group includes research directors of two most important national Translational Medicine (FIMM, 
Director Prof. Kallioniemi) and Biosciences institutes (Institute of Biotechnology, Director Prof. Mäkela), and 
includes 2 Academy of Finland Professors (KA & HJ). International cutting edge performance is evident from 
the involvement of 6 PIs in Finnish Centers of Excellence (Cancer Biology, KA, KO, ML; Translational Genome 
Scale Biology, OK, TM, PO). Furthermore, CANBIO researchers publish with high frequency in top-tier 
scientific journals (which include Nature, Cell and Science journals), are rewarded significant national and 
international research grants (Academy of Finland, Marie Curie, FP7, IMI, ESFRI) achieve prestigious prizes 
(including Anders Jahre Senior Medical Prize 2010 to KA; AACR Team Science Award 2008 for the 
development of CGH to OK) and carry significant patents for seminal discoveries and research products in 
the cancer biology field advancing to clinical trials. All PIs have gained training in top international institutes 
often in the United States, and within high profile research laboratories (Whitehead Institute, NIH, UCSF, 
Yale, CRUK, Stanford University, among others). This research consortium therefore represents the most 
competitive Finnish PIs in the field of cancer biology, hence the choice to participate in category 1. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): The 
CANBIO Research Consortium represents a powerful mix of principal investigators combining international 
cutting-edge research in the fields of cancer research.  The consortium includes both senior, established 
group leaders and a number of recently established group leaders with significant potential. During the 
evaluation period, several collaborative research projects have been carried out and initiated within this 
consortium that brings together researchers with excellence in cell, molecular and cancer biology, model 
systems, and state-of-the-art genome-scale technologies. This research has made fundamental 
contributions to the understanding of the molecular mechanisms responsible for cancer pathogenesis and 
3 SCIENTIFIC FIELDS OF THE RC 
4 RC'S PARTICIPATION CATEGORY 
5 DESCRIPTION OF THE RC'S RESEARCH AND DOCTORAL TRAINING 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
progression.  The ongoing and planned studies are expected to reveal novel pathways of cancer 
development and result in new innovative strategies for cancer therapies.  
 
The consortium supports researcher careers at all stages. The principal investigators within this consortium 
have a strong track record of the leadership and management of graduate schools and all of the PIs as well 
as many postdoctoral researchers are actively involved in organisation of courses and international 
scientific symposia. The consortium provides an excellent environment for Ph.D. and postdoctoral training, 
where interactions between researchers and students further escalate at all levels via both national and 
international networks. The more formal training of the Ph.D. students is received by participation in 
courses provided by the Helsinki area graduate schools. As a result of these activities and excellent 
mentoring, several previous students and postdocs trained in the groups of this consortium are currently 
working as postdocs in the top-level universities and institutes in US and Europe and many hold leading 
positions and professorships in research institutes and university departments in Finland and abroad. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): The RC has been active in supporting researcher careers at all stages. The principal 
investigators within this RC have a strong track record of activity in graduate schools and international 
training events. Several of the PIs are actively involved in the leadership and management of graduate 
schools and programs: PO (dean and board member of the Helsinki Biomedical Graduate School, HBGS 
2007-, as well as board member in the MD/PhD program, Faculty of Medicine), TM (dean (2002-2007) and 
chairman of the board 2007-, HBGS), OK (board member, HBGS 2008-, board of a new Nordic-EMBL joint 
PhD training initiative), JK-O (dean 1998-2002, HBGS; chairman of the board, MD/PhD program, Faculty of 
Medicine). 
 
The RC provides an excellent training environment, where interactions between researchers and students 
are enabled at all levels via both national and international networks. The graduate training activities linked 
to the RC have included: i) graduate  and postgraduate mentoring ii) active organisation of courses and 
international scientific symposia iii) international researcher recruitment and training in collaboration with 
the Biocenter Finland and Nordic EMBL Molecular Medicine Network. The excellent mentorships within 
groups of the RC has allowed the transition of students and postdocs to prestigious research sites in Finland 
and abroad, and many now hold leading positions or professorships.  
 
The RC has trained and educated 25 PhDs during years 2005-2010, which makes approximately 4% of 
dissertations within the Faculty of Medicine. The contribution of the PIs of this RC to the leadership and 
development of the largest biomedical graduate school in the country and the MD/PhD program has been 
essential to improve the quality of doctoral training within the University of Helsinki. Moreover, with its 
several international networks and training activities this RC has significantly contributed to the increasingly 
international angle of the doctoral training at the University of Helsinki. 
Keywords: Cancer research, Functional cancer genomics, Translational Genome-scale cancer biology, 
Mouse molecular cancer genetics, Tumor Invasion and metastasis, Tumor microenvironment, Signal 
transduction 
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Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): At the national level, Drs Kari Alitalo, Olli 
Kallioniemi, Emmy Verschuren, Pipsa Saharinen and Juha Klefström (toivottav en unohtanut ektään) 
participate in the development of Finnish infrastructures as part of the national Biocenter Finland plan. The 
infrastructures Viral Gene Transfer (KA), LentiGEMM (JK - coordinator), EV, PS) and Translational 
Technologies (OK -coordinator) will develop new state-of-art technologies and services for in vitro and in 
vivo gene transfer purposes as well as biobanking and validation of novel therapeutics. An essential part of 
the infrastructure development is national level training for graduate students and postdocs. All 
infrastructure networks are committed to organise annual minisymposia featuring international experts as 
well as theory-based and hands-on graduate school courses at national level (usually coordinated and 
advertised through FinBioNet). These courses are sponsored by Biocenter Finland and local graduate 
schools. The coordination positions and memberships of 5 PI’s of CANBIO will ensure that these training 
possibilities, which form cornerstones for modern molecular cancer biology research, and they will be 
advertised and offered for students, postdocs and PI’s in the RC. Furthermore, all CANBIO PIs actively 
participate in the development of the University of Helsinki undergraduate and graduate school curricula 
(Dean Päivi Ojala). All PIs are committed to transfer significant cancer biology expertise to the research 
community, fostering a collaborative attitude aimed towards excellence. Students and postdocs attend and 
present at high-profile international cancer meetings (Keystone, Cold Spring Harbour, AACR), and often 
collaborate with international expert laboratories. International mobility is promoted, evident also in the 
involvement of CANBIO PIs in the LERU program (Paivi Ojala), the Nordic EMBL partner PhD student 
program (FIMM PIs) and EU Framework programs (most PIs) and the IMI public private partnership (JK, OK, 
EV), where postdoc supervision will be shared between, and therefore bridge, EU-wide industry and 
academic research. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): The scientific productivity and activity of the RC can be assessed by the level of 
scientific articles, reviews (international and national), grants and awards obtained, presentations at 
international meetings, external reviewer or advisory tasks for funding organizations and research 
institutes and leadership roles in scientific communities.  
  
Doctoral training can be assessed by the number of students currently in training (undergraduate and 
graduate) and number of completed grades (Ph.D.). The number of graduate students participating in 
Academy of Finland funded graduate schools will be informative in terms of ability of the students to 
compete for access to top-tier training programs, and their participation in structured, mentored research 
training. International students and postdoctoral fellows should be listed separately, as this is an indicator 
of the capability of the RC to attract international talent. In addition, the participation of the PI:s in the 
graduate training programs as directors, other leadership and evaluation roles, and organization of 
graduate training activities and courses should be listed.  
  
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
 
 
5 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
The publication strategy of the RC distinctly weighs on publication of original, novel, well-designed 
comprehensive studies on the molecular and cellular aspects of cancer biology. The publication profile 
consists of high-ranking, peer-reviewed international journals. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Genome-Scale Cancer Biology (ACRONYM: CANBIO)
RC-LEADER K. Alitalo
CATEGORY 1
Group Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
1 alitalo Alitalo Kari x Academy Professor Faculty of Medicine, Resereach Programs Unit
2 kallioniemi Kallioniemi Olli x Professor Institute for Molecular Medicine Finland
3 mäkelä Mäkelä Tomi x Professor Faculty of Medicine, Resereach Programs Unit
4 lehti Lehti Kaisa x Academy Researcher Faculty of Medicine, Resereach Programs Unit
5 saharinen Saharinen Pipsa x Academy Researcher Faculty of Medicine, Resereach Programs Unit
6 ojala Ojala Päivi x Research Professor Faculty of Medicine, Resereach Programs Unit
7 laiho Laiho Marikki x Professor Faculty of Medicine, Resereach Programs Unit
8 klefstrom Klefström Juha x Academy Researcher Faculty of Medicine, Resereach Programs Unit
9 verschuren Verschuren Emmy x Group Leader Institute for Molecular Medicine Finland
10 laakkonen Laakkonen Pirjo x Group Leader Faculty of Medicine, Resereach Programs Unit
11 ristimäki Ristimäki Ari x Professor
Faculty of Medicine, Resereach Programs Unit, 
Haartman Institute
12 keski-oja Keski-Oja Jorma x Professor Faculty of Medicine, Resereach Programs Unit
13 joensuu Joensuu Heikki x Professor Faculty of Medicine, Resereach Programs Unit
14
holmberg-
still
Holmberg-Still Carina x Academy Researcher Faculty of Medicine, Resereach Programs Unit
15 monni Monni Outi x Academy Research Fellow Faculty of Medicine, Resereach Programs Unit
16 salvén Salvén Petri x Group Leader Faculty of Medicine, Resereach Programs Unit
17 kuznetsov Kuznetsov Sergey x Group Leader Institute for Molecular Medicine Finland
18 koli Koli Katri x Group Leader Faculty of Medicine, Resereach Programs Unit
19 alitalo Tammela Tuomas Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
20 alitalo D'Amico Lago Gabriela Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
21 alitalo Tvorogov Dennis Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
22 alitalo Yamamoto Masahiro Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
23 alitalo Anisimov Andrey Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
24 alitalo Jeltsch Michael Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
25 alitalo Wiener Zoltan Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
26 alitalo Kivelä Riikka Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
27 alitalo Leppänen Veli-Matti Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
28 kallioniemi Wolf Maija Postdoctoral Researcher Institute for Molecular Medicine Finland
29 mäkelä Ekman Niklas Postdoctoral Researcher
Faculty of Medicine, Resereach Programs Unit, 
Finnish Medical Agency
30 mäkelä Katajisto Pekka
Doctoral candidate, 
Postdoctoral Researcher
Faculty of Medicine, Resereach Programs Unit, 
Whitehead Institute MIT
31 mäkelä Ollila Saara Postdoctoral Researcher Institute of Biotechnology
32 mäkelä Vallenius Tea Doctoral candidate, 
Postdoctoral Researcher
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
33 mäkelä Westerling Thomas
Doctoral candidate, 
Postdoctoral Researcher
Faculty of Medicine, Resereach Programs Unit, 
Dana-Farber, HMS
34 ojala Sarek Grzegorz Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
35 laiho
af Hällström 
(ent. Kiviharju)
Taija Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
36 laiho Band Arja Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
37 klefstrom Saarikoski Sirkku Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
38 klefstrom Tervonen Topi Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
39 verschuren Särkioja Merja Postdoctoral Researcher Institute for Molecular Medicine Finland
40 laakkonen Rivinoja Antti Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
41 laakkonen Lammi Johanna Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
42 keski-oja Hyytiäinen Marko Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
43 keski-oja Makarov Andrey Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
44 joensuu Bono Petri Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
45 holmberg-stillHamer Geert Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
46 monni Lepikhova Tatiana Postdoctoral Researcher Faculty of Medicine, Resereach Programs Unit
47 alitalo Zheng Wei Doctoral candidate Faculty of Medicine, Resereach Programs Unit
48 alitalo Hyvönen Ville Doctoral candidate Faculty of Medicine, Resereach Programs Unit
49 alitalo Nurmi Harri Doctoral candidate Faculty of Medicine, Resereach Programs Unit
50 alitalo Heloterä Hanna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
51 ojala Pekkonen Pirita Doctoral candidate Faculty of Medicine, Resereach Programs Unit
52 alitalo Holopainen Tanja Doctoral candidate Faculty of Medicine, Resereach Programs Unit
53 alitalo Zarkada Georgia Doctoral candidate Faculty of Medicine, Resereach Programs Unit
54 alitalo Bry Maija Doctoral candidate Faculty of Medicine, Resereach Programs Unit
55 kallioniemi Ojala Kalle Doctoral candidate Institute for Molecular Medicine Finland
56 kallioniemi Edgren Henrik Doctoral candidate Institute for Molecular Medicine Finland
57 kallioniemi Kilpinen Sami Doctoral candidate Institute for Molecular Medicine Finland
58 mäkelä Laajanen Kaisa Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
59 mäkelä Helenius Katja Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
60 mäkelä Kuuluvainen Emilia Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
61 mäkelä Kovac Bianca Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Genome-Scale Cancer Biology (ACRONYM: CANBIO)
RC-LEADER K. Alitalo
CATEGORY 1
Group Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
62 mäkelä Yang Ying Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
63 mäkelä Vaahtomeri Kari Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
64 mäkelä Udd Lina Doctoral candidate
Faculty of Medicine, Resereach Programs Unit, 
Inst. Of Biotechnology
65 mäkelä Londesborough Anou Doctoral candidate Faculty of Medicine, Resereach Programs Unit
66 mäkelä Ventelä Eeva Doctoral candidate Faculty of Medicine, Resereach Programs Unit
67 lehti sugiyama Nami Doctoral candidate Faculty of Medicine, Resereach Programs Unit
68 lehti Meller Pipsa Doctoral candidate Faculty of Medicine, Resereach Programs Unit
69 saharinen Lampinen Anita Doctoral candidate Faculty of Medicine, Resereach Programs Unit
70 ojala Cheng Fang Doctoral candidate Faculty of Medicine, Resereach Programs Unit
71 laiho Järvinen Päivi Doctoral candidate Faculty of Medicine, Resereach Programs Unit
72 laiho Jäämaa Sari Doctoral candidate Faculty of Medicine, Resereach Programs Unit
73 laiho Peltonen Karita Doctoral candidate Faculty of Medicine, Resereach Programs Unit
74 laiho Moore (Syrjäkari) Henna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
75 klefstrom Eskelinen Vilja Doctoral candidate Faculty of Medicine, Resereach Programs Unit
76 klefstrom Nieminen Anni Doctoral candidate Faculty of Medicine, Resereach Programs Unit
77 klefstrom Partanen Johanna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
78 klefstrom Marques Elsa Doctoral candidate Faculty of Medicine, Resereach Programs Unit
79 verschuren Lahtela Jenni Doctoral candidate Institute for Molecular Medicine Finland
80 laakkonen Chernenko Anastasiya Doctoral candidate Faculty of Medicine, Resereach Programs Unit
81 laakkonen Karhemo Piia-Riitta Doctoral candidate Faculty of Medicine, Resereach Programs Unit
82 ristimäki Heinonen Mira Doctoral candidate Faculty of Medicine, Resereach Programs Unit
83 ristimäki Böckelman Camilla Doctoral candidate Faculty of Medicine, Resereach Programs Unit
84 ristimäki Thiel Alexandra Doctoral candidate Faculty of Medicine, Resereach Programs Unit
85 ristimäki Mrena Johanna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
86 keski-oja Tatti Olga Doctoral candidate Faculty of Medicine, Resereach Programs Unit
87 joensuu Waltari Marika Doctoral candidate Faculty of Medicine, Resereach Programs Unit
88 joensuu Sihto Harri Doctoral candidate Faculty of Medicine, Resereach Programs Unit
89 joensuu Puputti Marjut Doctoral candidate Faculty of Medicine, Resereach Programs Unit
90 joensuu Lauttia Susanna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
91
holmberg-
still
Matilainen Olli Doctoral candidate Faculty of Medicine, Resereach Programs Unit
92 monni Heinonen Henna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
93 salvén Fang Shetong Doctoral candidate Faculty of Medicine, Resereach Programs Unit
94 salvén Ristolainen Heikki Doctoral candidate Faculty of Medicine, Resereach Programs Unit
95 salvén Wei Jing Doctoral candidate Faculty of Medicine, Resereach Programs Unit
96 koli Kantola Anna Doctoral candidate Faculty of Medicine, Resereach Programs Unit
 1 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 2 MATERIAL  
 
 
 
 
Name of the RC’s responsible person: Alitalo, Kari 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Genome-Scale Cancer Biology, CANBIO 
The RC’s research represents the following key focus area of UH: 6. Kliininen tutkimus – Clinical research 
Comments for selecting/not selecting the key focus area:  
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The Genome-Scale Cancer Biology (CANBIO) Research Consortium contains 18 internationally acclaimed 
research groups that focus on one common goal: the discovery and validation of new mechanisms and 
targets in human cancer, and translation of the results into medical benefits. This research consortium 
represents a powerful mix of principal investigators, ranging from prominent senior group leaders to a 
number of recently established group leaders with significant potential, and complementary cutting-
edge research and technologies in the fields of basic, translational and clinical cancer research. 
 
It is evident that new strategies to attack cancer are increasingly based on studies of tumours in the 
context of their microenvironment and interactions with host tissues. Growth of blood vessels 
(angiogenesis) is crucial for cancer progression, and blocking this process leads to improved outcomes in 
some forms of human cancer. The growth of lymphatic vessels (lymphangiogenesis) is intimately 
associated with metastatic spread of tumour cells into lymph nodes, which may serve as launch pads for 
further systemic metastasis. More recently it has become evident that also other host cell types have 
active roles in tumour progression and that they could serve as therapeutic targets. Also cell-cell and 
cell-ECM interactions within the tumour have a major impact on tumour growth and malignancy as well 
as on cell migration, invasion, and clonal evolution of cancer. Furthermore, tumour cells in some cases 
take on new characteristics through cellular reprogramming and acquisition of properties of stem cells. 
Invasion of tumour cells can occur as a process involving many cancer cells, called collective cell 
invasion, which can be studied only in 3D and in vivo contexts. The CANBIO research consortium has 
brought together innovative in vitro, ex vivo and in vivo models (including multiple mouse cancer 
models and recently also simpler animal models such as Xenopus laevis, Danio rerio, and C .elegans) and 
cutting-edge high-throughput genome-scale cancer biology and chemical biology technologies to 
investigate the tumour in its microenvironment, to perform systematic analysis of factors contributing 
to cellular signalling, reprogramming, migration, and invasion upon genetic changes. Additionally, large 
clinical patient materials have been analyzed. The research has resulted in novel discoveries on cellular 
signalling including microenvironment-dependent signalling, on tumour suppressor genes, DNA damage, 
checkpoint regulation, angiogenesis, lymphangiogenesis, tissue remodelling and tissue/cellular 
reprogramming. Several prognostic markers of human malignancies have been identified and preclinical 
gene therapies to exploit the inherent vulnerabilities of cancer cells have been performed or are 
ongoing. Thus, our research consortium establishes a circuit from the discovery and analysis of 
oncogenic factors to testing their relevance in animal models and further to preclinical trials employing 
gene therapy with potential translational and therapeutic applications. Thus, the program provides a 
target discovery, validation and clinical translation platform for a number of excellent scientists. 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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During the 2005-2010 evaluation period, the members of the CANBIO RC have made fundamental 
contributions to the understanding of the molecular mechanisms responsible for cancer pathogenesis 
and progression. The research excellence and significance is best exemplified by the number of 
publications in top-tier scientific journals including Science, and Nature and Cell with subjournals or 
other journals with impact factor over 16.00 (26 publications) and the number of patents 
(approximately 80) based on seminal discoveries as well as potential drug candidates in the cancer 
biology field that are now advancing into clinical trials. The acquired knowledge of factors contributing 
to cell migration, invasion, reprogramming, and cellular signalling as a result of genetic changes provides 
a more integrative view of tumour pathogenesis and forms a strong basis for development of new 
innovative strategies for novel cancer therapies including personalized cancer care. 
 
The CANBIO RC has extensive collaboration between the research groups, which in many  
cases is based on the combination of their complementary technological and scientific know-how. 
Researchers in the CANBIO RC work at the leading edge of Finnish and international research on basic 
and clinical aspects of cancer.  The CANBIO RC includes research directors of two of important national 
research institutes (Institute for Molecular Medicine Finland (FIMM), Director Prof. Kallioniemi; Institute 
of Biotechnology, Director Prof. Mäkela), and two PIs have reached the most prestigious academic 
positions in Finland (Professors of the Academy of Finland; Alitalo, Joensuu).  International cutting-edge 
performance is evident from the involvement of seven principal investigators in Finnish Centers of 
Excellence (CoE in Cancer Biology: Alitalo, Keski-Oja, Laiho, Salven; and CoE in Translational Genome-
Scale Biology:  Kallionemi, Mäkelä, Ojala). Most of the more recently established group leaders (9) have 
held Research Fellow positions of the Academy of Finland during this evaluation period. In addition, core 
facilities such as the high-throughput services in FIMM (Kallioniemi), the Biomedicum Genomics Center 
(Klefström, Monni), the Biocenter Finland Genome-Wide Methods Network (Mäkelä) and the 
Biomedicum Imaging Unit (co-director Laiho) are directed by principal investigators of the CANBIO 
consortium. The CANBIO principal investigators have successfully obtained competitive funding from 
significant national and international research funding agencies (Academy of Finland, Sigrid Juselius 
Foundation, Finnish Cancer Organisations, Marie Curie Program, Human Frontier Science Program, EU 
Framework Program 7, EU Innovative Medicines Initiative, and ESFRI) and been awarded prestigious 
prizes (such as Anders Jahre Senior Medical Prize 2010, Alitalo; AACR Team Science Award 2008, 
Kallionemi). 
 
The joint publication record of the CANBIO consortium reflects the extensive collaborations among 
member laboratories during 2005-2010 (56 joint publications). The focus and quality of the research in 
the CANBIO consortium will be further improved during the coming years, as a result of the recent 
and/or ongoing establishment of state-of-the-art infrastructure core facilities, technology platforms and 
research models by members of the consortium. Additionally, as one third of the 18 member groups 
have been established after 2005 (Holmberg-Still, Koli, Kuznetsov, Lehti, Saharinen, Verschuren), several 
research projects and collaborations are still at their early stages, yet provide significant potential to 
contribute to the common future goals of the CANBIO consortium on excellence in cancer biology 
research. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
The CANBIO groups will organise frequent bilateral as well as less official meetings on scientific topics. 
Along with the host organizations, we will organize 2-3 scientific symposia annually on special interest 
topics. In addition, there will be an annual scientific meeting, where all members of the respective 
groups are expected to present their results. To facilitate and ensure scientific interaction between the 
PIs, the number of joint publications and joint research projects will be monitored. Thus, we believe that 
this consortium has significant capacity for renewal, and a capability to achieve scientific breakthroughs 
through interdisciplinary research collaborations. 
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  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
The doctoral candidates of the CANBIO RC have been recruited by distributing website or e-mail 
announcements of open position within the national (e.g. FinBioNet - Finnish Graduate School Network 
in Life Sciences) and international networks (e.g. via the Nordic EMBL Molecular Medicine Network). 
Multiple applicants directly applied to the research groups after finalizing their B.Sc. or M.Sc. degrees. 
The initial selection of the candidates is based on interviews, references by previous 
mentors/supervisors, and a probationary period of three to four months. The students selected to the 
CANBIO RC groups will then prepare, together with the PI, a research proposal of their PhD project, and 
can apply for admission to a suitable graduate school. Most of the graduate schools relevant for the 
CANBIO RC open a call for four-year doctoral training positions once a year in the fall. The online 
application includes an application form filled by the student, a research proposal, supervisor's form 
filled by the PI of the CANBIO RC, and an optional letter of recommendation for example by the 
student's Master's thesis supervisor. The student applications are graded by a graduate school 
admission panel that selects the best students to their program via evaluation of the scientific 
significance and feasibility of the suggested project, and the ability of the student to carry out the 
suggested PhD project. 
 
The CANBIO RC has focused on training of inter- and multidisciplinary scientists that are increasingly 
required for progress of biomedical sciences. The integrative research projects of the CANBIO RC have 
provided a fertile training platform for the next generation of scientists with multidisciplinary skills and 
expertise in translational research for biology, medicine and industry. The primary supervision is carried 
out by the PI together with senior staff scientists or postdoctoral fellows who provide training-through-
research on a daily basis in a supportive and inspiring training environment. All scientists in the CANBIO 
RC are committed to long-term and in-depth graduate training with ambitious goals. The CANBIO RC has 
been active in supporting researcher careers at all stages, and the principal investigators within this 
CANBIO RC have a strong track record of activity in graduate schools and international training events. 
Moreover, the doctoral candidates of the CANBIO RC have built a curriculum that is based on various 
types of courses in which they actively participate. Some of these are obligatory, but others are optional 
courses considered suitable for the PhD project area. 
 
Several of the PIs are actively involved in the leadership and management of graduate schools and 
programs: Ojala(dean and board member of the Helsinki Biomedical Graduate School, HBGS 2007-, as 
well as board member in the MD/PhD program, Faculty of Medicine), Mäkelä (dean 2002-2007 and 
chairman of the board of HBGS 2007-), Kallioniemi (board member, HBGS 2008-, board of a new Nordic-
EMBL joint PhD training initiative), Keski-Oja (HBGS dean 1998-2002; chairman of the board, MD/PhD 
program, Faculty of Medicine), Salven (professor in charge 2009-2010, The Master's Degree Program in 
Translational Medicine, Faculty of Medicine). 
 
The doctoral candidates are assigned a personal Thesis Committee that functions as the quality and 
progress evaluation system of PhD projects in the CANBIO RC. The purpose of the regular thesis 
committee meeting is to evaluate the progress and future plans of the PhD project and to support the 
student and supervisor for successful continuation of the project. The Thesis Committee has helped to 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
 4 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 2 MATERIAL  
 
 
design a personalized training portfolio for the student in the first thesis committee meeting. The Thesis 
Committee includes the student, the supervisor(s), and at least two external senior members. The 
mentoring is available all year round and the student submits a report annually.  The Thesis Committee 
also advises and mentors the doctoral candidate on one's choice of a post-doctoral career. 
 
The doctoral candidates and fresh doctorates within the CANBIO RC have been exposed to training of 
complementary skills such as scientific writing and presentation skills, research ethics, IP protection, 
technology transfer and industrial collaborations as well as entrepreneurial opportunities. The national 
and international scientific contacts and collaborations of the CANBIO RC PI's, including several national 
Centers of Excellence and EU research projects (both STREPs and IPs), have provided excellent support 
for promotion of research careers for the doctoral candidates/fresh doctorates and for international 
researcher mobility. CANBIO is thus able to give its students and post doctoral fellows a state-of-the-art 
scientific and methodological training at the highest professional level, and provide indispensable 
contacts with the international scientific community. These skill sets, scientific contacts, and motivations 
will be essential to meet sectoral needs of both academia and industry & health care thus giving the 
trained researchers the best possible future career prospects.  
 
Strengths 
The CANBIO RC provides an excellent training environment, where interactions between postdoctoral 
researchers and students are encouraged at all levels, including national and international networks. 
The training environment has been particularly good for graduate students, who have the possibility to 
learn advanced technologies, and to directly contribute to top-level science. Publication of top-level 
science is the best way to disseminate the knowledge and promote career development. Through the 
extensive collaborations within the CANBIO RC, graduate students have gained access to other 
laboratories and international research institutes, scientific conferences/workshops and short 
researcher exchanges (secondments). These have in part offered them with opportunities for 
postdoctoral studies. The PIs of the CANBIO RC have supervised over 15 Ph.D. dissertations in the 
University of Helsinki during the years 2005-2010, several of which have won national and international 
thesis-awards. The PIs thereby have a significant track record in promoting career development of PhD 
student-level scientists. As a result of these activities and excellent mentoring, several previous students 
and postdocs trained in the groups of the CANBIO RC are currently working as post-docs in the top-level 
universities and institutes in the US and Europe and many hold leading positions and professorships in 
research institutes and university departments in Finland and abroad. 
 
Challenges 
One particular challenge in need for more effective solutions is the decreasing interest amongst Finnish 
medical students towards a scientific career, or towards combining the careers of a researcher and a 
clinician (an article about this problem has recently been published Suomen Lääkärilehti (Finnish 
Medical Journal) vol.17;2009,p.1542-1544). Consequently, only few young M.D.'s currently enter 
research careers. The situation is especially worrying considering the current era of molecular medicine 
and genomics when there is a strong need for talented young clinicians capable of working at the 
interface of basic biomedical science and clinical research. This situation may delay the translation of the 
results of biomedical research from the bench to the bedside. Another issue is the relative lack of 
promising future career development options for the newly graduated Ph.D.s (of both M.Sc. or MD 
backgrounds). This is especially the case for those that want to continue in academic research. 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
Planned actions 
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The CANBIO RC combines researchers with exceptional experience in basic and translational research, 
and in clinical work in the Helsinki University Hospital. The CANBIO RC members have a good 
perspective and understanding of current problems. They can, and should, contribute to the efforts of 
our medical school to attract medical students to research, and they can provide active support to the 
MD/PhD program. These contributions are provided by the direct efforts of the CANBIO RC PIs 
themselves, as well as by the knowledgeable and gifted teaching personnel of the CANBIO RC research 
group members. Further development of the university's current efforts in creating tenured research 
position system is another high priority goal of the CANBIO RC. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
The CANBIO RC research area has a highly significant societal impact. Cancer is a clinically debilitating 
disease, a major cause of morbidity and mortality in our western European society, with an increasing 
incidence especially in the aging population. Our patient population expects improved therapies, 
diagnostics and preventive measures. The society at large needs to cope with the increased costs 
associated with the treatment of the diseases and with the decision-making regarding types of 
therapeutic strategies offered.  
 
The CANBIO RC members have a long track record in cancer research, and are in an excellent position to 
provide expert opinion on the importance of scientific discoveries and emerging and new types of 
treatments. The CANBIO RC represents an instrument for the translation of the significance of its own 
scientific innovations, and those of others, to the wider community. The scientific achievements of the 
CANBIO RC are communicated at different levels, targeting scientists, academic institutions, industry 
and the general public. 
 
The CANBIO RC members contribute to raising awareness of scientific cancer progress, science policy 
and ethical issues by participation in public and more focused forums, writing editorials and other 
general format publications. The CANBIO RC members are committed to transmitting important findings 
to the public, through proactive communication with the public media. 
 
Several patient target groups, with unique needs and characteristics, will directly benefit from CANBIO’s 
research.  The majority of cancer patients are diagnosed in the aged population, which is expanding. The 
CANBIO RC contributes to the societal health objectives, and furthermore provides service to otherwise 
under-represented patient groups at increased risk of cancer. The benefit to these patient groups will 
have a larger effect on families and work environments as a whole. 
 
Accompanying the identification and functional characterization of genes involved in cancer, 
opportunities and challenges emerge to improve health and to stimulate industrial applications, 
particularly in diagnostics, health technology, and drug development. Based on its discovery-focused 
projects, the CANBIO RC should provide tools and small-molecule lead molecules of interest for the 
biotechnology industry. Biotechnology companies are increasingly using genetically defined animal 
models that recapitulate the natural history and mechanistic events of human neoplasias to test their 
drugs before engaging in costly clinical trials. The dissemination of these tools and technologies to 
industrial partners will be promoted to attract potential biomedical industrial partners interested in the 
exploitation of the CANBIO results. The pharmaceutical industry has great interest to develop therapies 
aimed at inhibiting tumour growth and metastasis, for which they seek academic collaborations to 
promote knowledge on candidate cancer targets. The CANBIO project is thereby expected to yield 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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significant new Intellectual Property. The validation of novel and biologically relevant targets for 
inhibition of cancer will also include proof-of-principle evaluation of the targetability and drugability of 
the candidate molecules. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
A significant improvement over and above the current CANBIO RC activities would be realized by 
founding a Comprehensive Cancer Center, which is currently lacking in Finland. The main focus of a 
Comprehensive Cancer Center would constitute an academic discovery base, coupled with clinical 
research in cancer. These activities should be associated with training of scientists for basic and clinical 
cancer research, as well as cancer prevention. It should also provide continuing education and training 
of health care professionals, offer a spectrum of state-of-the-art cancer care and services, with a 
particular focus on the cancer prevention methods and on accrual of patients to cancer clinical trials. 
This would further facilitate the distribution of knowledge of the cancer problem, and its solutions, to 
the community, engage narrative discussions of special or underserved populations and wide 
distribution of pertinent cancer incidence and mortality data. Further, such formal structures should 
advance collaborations with non-profit or for-profit outreach programs and organizations. 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
The translation of basic biology discoveries to the clinic requires a broad range of expertise, emphasising 
the need for collaborations between different groups. Collaborations within the CANBIO RC have been 
established and resulted in at least 52 joint peer-reviewed publications, many of them in top tier 
international journals, involving at least two PIs mentioned above during the period 2005-2010. Four PIs 
from the CANBIO RC (Alitalo, Keski-Oja, Laiho, and Salven) also formed a core of the highly successful 
Center of Excellence (CoE) in Cancer Biology operating during 2000-2011 that primarily focused on 
cancer invasion, metastasis, angiogenesis, DNA damage and colon cancer. Nine research groups from 
CANBIO RC were involved in the Molecular Cancer Biology Program at the Faculty of Medicine 
coordinated by Academy Professors Kari Alitalo and Lauri Aaltonen and Professor Tomi Mäkelä. Seven of 
these PIs are also involved in the Research Program in Genome-Scale Biology focusing on genome-scale, 
high-throughput biological research and its translation into medical benefits. Four PIs, Klefström, 
Verschuren, Kuznetsov, and Saharinen together with others joined to form a Biocenter Finland 
Infrastructure Emerging Technology consortium for 2011-2012 aiming to develop a lentiviral platform to 
create somatic Genetically Engineered Mouse Models (coordinator – J. Klefström). Kari Alitalo is 
involved in the Viral gene transfer and cell therapy network, while T. Mäkelä and O. Kallioniemi are 
coordinators for the Genome-wide methods and Translational technologies platforms, respectively. 
Participating PIs of the CANBIO RC were also involved in several major international collaborations such 
as European FP7 consortia (GENICA – Kallioniemi, Kuznetsov), most noticeably the Innovative Medicines 
Initiative Joint Undertaking (IMI, coordinator – Verschuren). In the latest IMI project, Finland is 
represented by 4 PIs (Verschuren, Klefström, Monni, Kallioniemi), and all of them are participating in the 
CANBIO RC. 
 
A total of 15 postgraduate students from CANBIO RC participating groups defended their PhD thesis in 
2005-2010. Students in CANBIO participating groups are mostly affiliated with the Helsinki Biomedical 
Graduate School (HBGS) and the Helsinki Graduate Program in Biotechnology and Molecular Biology 
with the former one largely steered by the CANBIO PIs. HBGS is currently headed by Päivi Ojala. Other 
CANBIO PIs participate in building the curriculum of the school, which enrolls approximately twenty 
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students each year for a 4-year study corresponding to the highest educational standards. Starting in 
2010, a new joint PhD program, Nordic EMBL Graduate School was established between three nordic 
EMBL-affiliated institutes: the Institute for Molecular Medicine Finland (FIMM, Helsinki), Centre for 
Molecular Medicine Norway (NCMM, Oslo), and Molecular Infection Medicine Sweden (MIMS, Umea). 
Students selected in the program (2 students for FIMM in 2010) first go through two three-month 
rotations in different labs, and then choose the lab for the main PhD study. Students receive a salary 
during the first year from the host institute after which they are expected to enroll in one of the local 
graduate schools. 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
CANBIO promoted research mobility through multiple routes during '05-'10. First, individual CANBIO 
participating PIs encouraged their successful PhD student to venture overseas for postdoctoral studies. 
About 20 individuals from CANBIO groups took postdoctoral positions outside Finland after receiving a 
PhD. Second, CANBIO PIs recruited over 40 foreign students and postdocs during the same period. Most 
noticeably, two junior international PIs (Kuznetsov and Verschuren) from prestigious US institutions 
such as NIH and Genentech, have been recruited to FIMM and joined the CANBIO. The Nordic EMBL 
Graduate program described above also contributes to the research mobility as the recruitment to the 
program is carried out on the international scale and jointly coordinated between 3 Nordic research 
centers. 
 
To further promote international research mobility, the Nordic EMBL centers are preparing a Marie 
Curie Initial Training Networks funding application. If approved, this grant will support internationally 
competitive students to carry out a collaborative research between the EMBL sites. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
The CANBIO RC consists of 18 groups located in the Meilahti Biomedical Campus in the Research 
program’s Unit (RPU) at Biomedicum Helsinki and in the Institute of Molecular Medicine Finland (FIMM), 
and in the Institute of Biotechnology (BI) in the Viikki Bioscience Campus. Within CANBIO each group 
forms an independent unit responsible for its own funding and research, while having committed to 
actively participate in joint activities of the RC.  
 
The infrastructure for the CANBIO RC is excellent. FIMM (director Kallioniemi), BI (director Mäkelä), and 
Biocentrum Helsinki (Alitatlo, Kallioniemi, Mäkelä) operate key local and national infrastructures, such 
as the FIMM hosted advanced high-throughput screening systems. The CANBIO RCs PIs are key 
contributors to Biocenter Finland networks (www.biocenter.fi) of Genome-wide methods (coordinator 
Mäkelä), Translational technologies (coordinator Kallioniemi), Viral gene transfer (Alitalo) and Lentiviral 
platform for creating somatic genetically engineered mouse models (LentiGEMM, coordinator 
Klefström; Kuznetsov, Saharinen, Verschuren). The CANBIO RC groups have access to local core facilities 
including animal facilities, genotyping, next-gen sequencing (Illumina GAII x 3, Hiseq, Solid 2), 
microarrays (Affymetrix, Illumina, Agilent), chemical biology, high-throughput screening of siRNAs/ORFs, 
lenti/retro/adeno-associated virus vector units (e.g. via Biomedicum Genomics, 
www.biomedicumgenomics.fi/home, directed by Monni, Klefström), iPSC laboratory, proteomics, 
metabolomics, molecular imaging unit with cell/animal/tissue imaging, bioinformatics, tissue 
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microarrays, biobanks and translational technologies (e.g. 
www.biomedicum.fi,www.fimm.fi/en/technologycentre/, www.helsinki.fi/biocentrum/core.htm). 
 
In addition to research duties, PIs of the CANBIO RC participate in teaching and have strong track 
records of activity in graduate schools and international training events. Several of the PIs are actively 
involved in the management of graduate schools; Ojala (dean & board member of HBGS '07-), Mäkelä 
(dean '02-'07, chairman of the board '07-, HBGS), Kallioniemi (board member, HBGS '08-, board of a new 
Nordic-EMBL joint PhD training initiative). In addition, all PIs participate in various teaching activities at 
undergraduate levels (Depts. of Pathology and of Biomedicine), or in the graduate schools, varying from 
10 to 30 hours per term, and organize regular student progress follow-up meetings (e.g. Cancer Biology 
Progress Reports). In addition, the groups have their own meetings. 
 
The strengths of the CANBIO RC are the high level of competence of the PIs, both scientifically and via 
cutting-edge technology development, as well as their success in obtaining grants and academic 
positions. The CANBIO RC bridges three institutes and departments at the University of Helsinki (RPU, 
FIMM-EMBL, BI) bringing access to a collection of state-of-the-art technological facilities shared without 
barriers between the laboratories. A critical mass of scientific expertise (over 100 researchers), with 
diverse backgrounds in medicine, biochemistry, genetics, virology, as well as cell and molecular biology, 
is created in cancer research within the CANBIO RC, something that is very important in a small country. 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
Significant challenges are the short duration of the research positions (only 2 to 5 yrs; often non-
renewable in spite of scientific success), and of research funding. This results in the threat of losing 
seminal young scientists abroad or to other universities. Indeed, most PIs have temporary (2-5 yr) 
positions, and permanent (or tenured) positions are very rare. Due to the short-term, unpredictable 
funding, a very significant part of the work needs to be devoted to writing reports and new grant 
applications. In addition, the university administration is exhaustive. The laboratory space is limiting, 
and in the Biomedicum Helsinki, the space allocation is not optimal. The group sizes and funding levels 
change frequently, which imposes new arrangements.  
 
The CANBIO RC will continue to invest their best efforts to maintain technology service units in the 
institutions at the global frontline, but in addition to new technology development, outside funding is 
required. The challenges related to short-term research funding and positions require actions at a higher 
level than the CANBIO RC. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
Participating groups of the CANBIO RC are parts of three research institutes at the University of Helsinki, 
including the Research Programs Unit of the Medical Faculty, the Institute for Molecular Medicine 
Finland (FIMM-EMBL partnership) and the Institute for Biotechnology. The majority of the groups in the 
CANBIO RC participate in centers of excellence (Cancer Biology (CB), Translational Genome Scale Biology 
(TGSB) and/or in common research programs (Molecular Cancer Biology (MCB), Genome Scale Biology 
(GSB). The PIs within this CANBIO RC have a strong track record of scientific leadership and management 
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of graduate schools and all PIs, as well as many postdoctoral researchers, are actively involved in 
organization of courses and international scientific symposia. 
 
CANBIO RC primarily represents an academic consortium with a goal to ensure critical mass and 
stimulate new ideas and collaborations and foster outstanding science. Therefore the management 
framework is aimed to link project components and enable efficient communication between the 
research groups, with primary responsibility with the coordinator. In the 2005-2010 period there has not 
been administrative assistance, but see also strategic plans.The CANBIO groups organise frequent 
bilateral as well as less official meetings on scientific topics, and have been active in arranging scientific 
symposia (not listed in the evaluated activities) including one larger national meeting annually. The PIs 
independently apply for research funding and have a solid record of directing independent research. The 
PIs take active part in coordination of and participation in international research programs (EU 
frameworks, European Strategy Forum on Research Infrastructures). The PIs have a strong track of 
activity in graduate schools, in international training events and in the leadership and management of 
research programs. Financial and administrative management of CANBIO RC activities are the 
responsibility of administration units of host institutes. 
 
The majority of the groups in the CANBIO RC maintain extensive collaborations as participants of centers 
of excellence and/or in common research programs. Collaborations involve cooperative projects (joint 
publications in high-profile journals), technology transfer (methodological and scientific expertise 
exchange between labs), sharing resources (mice, reagents, common MTAs), common technology 
platforms (siRNA and ORF libraries, lentviral expression, high throughput and high-content screening). 
PIs also serve as mentors or thesis committee members for doctoral students from other participating 
research groups, thus contributing to the doctoral thesis work performed within the CANBIO RC. 
 
The PIs have broad expertise in molecular and cell biology, mouse models of cancer, structural biology 
and cancer therapeutic concepts and possess in-depth know-how of genomics, proteomic and 
bioinformatics. The high-throughput and translational infrastructure of the CANBIO RC provides an 
excellent platform for seminal scientific discoveries and their ultimate translation into cancer diagnostics 
and treatment. The CANBIO RC includes research directors of two national Translational Medicine 
(FIMM) and Biosciences institutes (Institute of Biotechnology). 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
Specific care must be taken that novel technologies and scientific endeavors are propagated across the 
CANBIO RC. In order to effectively contribute to the CANBIO’s success, problem solving sessions and 
scientific meetings are held regularly as integral parts of the research programs (CB, GSB). The 
challenges involved include the fact that the collaborative plans and efforts may not optimally meet 
objectives of individual groups. To facilitate and ensure scientific interaction between the participants, 
the number of joint publications and joint research projects will be monitored. 
 
 
 
 
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
7 EXTERNAL COMPETITIVE FUNDING OF THE RC 
 10 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 2 MATERIAL  
 
 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 15600586 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 2291772 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 4911032 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010:  
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Magnus Ehrnrooth Foundation 
- Sigrid Jusélius Foundation 
- Liv och Hälsa 
- Johansson Foundation 
- HY rahastot 
- Syöpäjärjestöt 
- Association for International Cancer Research 
- Emil Aaltonen 
- Tieteellisten seurain valtuuskunta 
- Yrjö Jahnsson Foundation 
- Magnus Ehrnrooth foundation 
- STVY-foundation 
- Sydäntutkimussäätiö 
- total amount of funding (in euros) from the above-mentioned foundations: 6851204 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations: mdRNA 
- The International Human Frontier Science Program Organization 
- ESF Cost 
- total amount of funding (in euros) from the above-mentioned funding organizations: 652468 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: Biocentrum Helsinki 
- Biokeskus Suomi 
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- CIMO Kansainvälisen liikkuvuuden ja yhteistyön keskus 
- Ministry of Education and Culture funded doctoral programme positions 
- University of Helsinki Funds 
- Institute of Molecular Medicine Finland 
- HUS 
- total amount of funding (in euros) from the above-mentioned funding organizations: 18991088 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
The CANBIO RC research will increasingly employ state of the art infrastructures for genomics, genome-
scale and chemical biology, bioinformatics, and translational research. In addition, the RC will continue 
to develop technologies for high-content cancer cell biological assays. The early-stage application of 
these new types of cell array technologies to the questions posed by the CANBIO RC investigators will 
provide new discovery opportunities for the CANBIO RC. Conversely, the biological questions posed by 
the CANBIO RC investigators will help drive the technology development. We will explore newer 3D 
cancer model systems, co-cultures mimicking support from the tumour microenvironment, short term 
primary cultures and ex-vivo tissue implants as well as animal model systems to validate the drug testing 
and chemical biology discoveries. Together, these efforts will generate model systems to facilitate 
translational therapeutic studies as well as in vivo validated leads and personalized medicine strategies 
for clinical trials. We will also apply integrative bioinformatics to link the genome-scale biology 
exploration with the cancer genomics, epigenomics and transcriptomics studies of human uncultured 
tumours in order to prioritize genes for further biological studies based on both in vitro causal evidence 
and potential in vivo relevance. Bioinformatic predictions and basic research discoveries will be 
validated in clinical specimens, using e.g. immunohistochemical staining of the target proteins in large-
scale arrayed biobanks applying tissue microarray technology and web microscopy. Collaborations with 
the Helsinki University Central Hospital (HUS) Oncology clinic and the Pathology Laboratories are strong 
and crucial for translation of cancer research breakthroughs at the level of human tissue specimens, for 
advancement of personalized medicine and discussion of clinical trial ideas.  
 
The CANBIO RC focuses on taking advantage of critical mass and facilitation of scientific collaboration. 
The management framework links all project components and enables efficient communication 
between the research groups in an environment where all PIs have multiple funding sources and often 
multiple reporting obligations; the CANBIO RC participants span several University of Helsinki 
organizations (Research Programs Unit of the Faculty of Medicine, FIMM, Institute of Biotechnology). 
The scientific coordinator (Alitalo) holds overall responsibility of progress. Daily management of CANBIO 
activities will be the responsibility of an administrative coordinator with financial, administrative, 
scientific, educational and technological overview. Internal management of CANBIO activities and 
resources takes place within the CANBIO Steering Group consisting of the coordinator and all Principal 
Investigators. The Steering Group will discuss scientific collaborations and managerial issues including 
any possible alterations occurring in personnel or other resources of the CANBIO members. These 
include situations where there would be an interest to recruit a new PI/team into the CANBIO RC. All PIs 
will be committed to the CANBIO work including common tasks in reporting and arranging internal 
scientific activities. 
 
We believe that this consortium will be able to tackle key questions in cancer biology in a much deeper 
way than would be possible by one or two laboratories. The CANBIO RC presents a networked structure 
that is essential in a small country to reach an international world-class level. The research models and 
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technological capabilities will be shared without barriers between the laboratories. This will provide an 
excellent intellectual environment ideal for creativity as well as for researcher training. All biological 
material generated within the CANBIO-funded activities will be made available to larger scientific 
communities within e.g. Biocenter Finland or deposited in international repositories for e.g. open access 
plasmids and mouse strains. Protection of Intellectual Property is encouraged according to the host 
organizations regulations. The involvement of multiple institutions brings access to an impressive 
collection of state-of-the-art technological core facilities and the RC will also facilitate the new 
technology development needed for maintaining technology service units in the institutions in the 
global frontline. 
 
 
 
All the consortium members have contributed to the compilation of the material for the stage 2 
evaluation. Alitalo, Joensuu and Holmberg compiled information from all the consortium members on 
the focus and quality of the research. Ojala and Salven compiled the information on the practices and 
quality of doctoral training, Laiho and Klefström on the societal impact of research and doctoral training, 
and Kallioniemi, Verschuren, and Kuznetsov on international and national research collaboration and 
researcher mobility. Keski-Oja, Saharinen, and Lehti wrote the section on operational conditions, Mäkelä 
and Laakonen on leadership and management in the researcher community, and Alitalo contributed to 
the RC’s strategic action plan for 2011–2013. All the RC members provided information on their external 
competitive funding. Monni, Ristimäki, and Koli assembled the information on the contribution of RC 
members to the compilation of the stage 2 materials. 
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1 Analysis of publications 
 
- Associated person is one of Kari Alitalo ,  Olli-Pekka Kallioniemi ,  Tomi Mäkelä , Kaisa 
Irene Lehti ,  ,  Pipsa Ilona Saharinen ,  Päivi Ojala ,  Marikki Laiho , 
 Juha Klefström ,  Emmy Verschuren ,  Pirjo Maarit Laakkonen , 
 Ari Ristimäki ,  Jorma Keski-Oja ,  Heikki Joensuu ,  
Carina Holmberg-Still ,  Outi Monni ,  Petri Salven ,  Sergey Kuznetsov , 
 Katri Koli , ,  Tuomas Tammela ,  ,  
Gabriela Veronica D Amico Lago ,  Masahiro Yamamoto, Andrei Anisimov ,  Michael Jeltsch , 
,  Zoltan Wiener ,  Milla Riikka Kivelä ,  Veli-Matti Leppänen , 
 , Maija Wolf ,  Niklas Karl Ekman, Pekka Katajisto, Saara Ollila , 
 Tea Kaarina Vallenius ,  Thomas Örjan Westerling, Grzegorz Sarek , Taija Maria af 
Hällström ,  Arja Band ,  ,  Sirkku Talvikki Saarikoski ,  Topi 
Tervonen ,  Merja Annikki Särkioja , Antti Rivinoja ,  Johanna Lammi , 
Marko Timo Tapio Hyytiäinen ,  ,  Petri Bono ,  Geert Hamer 
,  Tatiana Lepikhova ,  Wei Zheng ,  Ville Hyvönen ,  Harri Juhani 
Nurmi ,  Hanna Heloterä ,  Pirita Maria Pekkonen ,  Tanja Talvikki Holopainen , 
 Georgia Zarkada , Maija-Elina Bry ,  Kalle Ojala ,  Henrik Edgren 
,  Sami Kalevi Kilpinen ,  Kaisa Laajanen ,  Katja Pirita Helenius , 
 Emilia Kuuluvainen ,  Ying Yang ,  Kari Vaahtomeri ,  Lina 
Viveca Udd ,  Eeva Sofia Ojanen ,  Nami Sugiyama ,  Pipsa Meller , 
Anita Lampinen ,  Fang Cheng ,  Päivi Järvinen ,  Sari Susanna Jäämaa , 
 ,  Karita Dolores Peltonen ,  Henna Maaria Moore ,  , 
Vilja Maria Eskelinen ,  Anni Irmeli Nieminen ,  Johanna Inkeri Partanen , 
 Elsa De Oliveira Marques , Jenni Salla Pauliina Lahtela ,  Anastasiya Chernenko , 
 Piia-Riitta Karhemo ,  Mira Marie Heinonen ,  Camilla Böckelman , 
Alexandra Thiel , Johanna Mrena, Olga Tatti ,  ,  Marika Johanna 
Waltari ,  Harri Sihto ,  Marjut Puputti ,  Susanna Lauttia ,  Olli 
Matilainen ,  Henna Kristiina Heinonen ,  Heikki Ristolainen , Jing Wei , 
 Anna Kantola ,  
 
                   Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 68 69 65 84 74 82 442 
A2 Review in scientific journal 2 4 2 2 3 6 19 
A3 Contribution to book/other compilations (refereed)   3 3 2  8 
A4 Article in conference publication (refereed) 1 2 2 2 2 2 11 
B1 Unrefereed journal article 5 5 6 4 3 6 29 
B2 Contribution to book/other compilations (non-refereed)    2 2  4 
B3 Unrefereed article in conference proceedings  1   2 1 4 
C2 Edited book, compilation, conference proceeding or special issue of 
journal 
  1    1 
D1 Article in professional journal  1 1   1 3 
D2 Article in professional hand or guide book or in a professional data 
system, or text book material 
     2 2 
E1 Popular article, newspaper article    1   1 
H1 Patents 1 1 1 1   4 
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2 Listing of publications 
A1 Refereed journal article 
2005 
Alhopuro, P, Ylisaukko-oja, S, Koskinen, W, Bono, P, Arola, J, Järvinen, HJ, Mecklin, J, Atula, T, Kontio, R, Mäkitie, A, Suominen, S, 
Leivo, I, Vahteristo, P, Aaltonen, L, Aaltonen, LA, Suominen, S 2005, 'The MDM2 promoter polymorphism SNP309T-->G and the risk of 
uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck', Journal of Medical Genetics, vol 42, 
no. 9, pp. 694-698. 
Alhopuro, P, Katajisto, P, Lehtonen, RJ, Ylisaukko-oja, S, Näätäsaari, L, Karhu, A, Westerman, AM, Wilson, JHP, de Rooij, FWM, 
Vogel, T, Moeslein, G, Tomlinson, IPM, Aaltonen, LA, Mäkelä, TP, Launonen, V 2005, 'Mutation analysis of three genes encoding novel 
LKB1-interacting proteins, BRG1, STRADalpha, and MO25alpha, in Peutz-Jeghers syndrome', British Journal of Cancer, vol 92, no. 
6, pp. 1126-1129. 
Alitalo, K, Tammela, T, Petrova, T 2005, 'Lymphangiogenesis in development and human disease', Nature, vol 438, no. 7070, pp. 946-
953. 
Andersson, J, Sihto, H, Meis-Kindblom, J, Joensuu, H, Nupponen, N, Kindblom, L  2005, 'NF1-associated gastrointestinal stromal tumors 
have unique clinical, phenotypic, and genotypic characteristics', American Journal of Surgical Pathology, vol 29, no. 9, pp. 1170-
1176. 
Atiye, J, Wolf, M, Kaur, S, Monni, O, Bohling, T, Kivioja, A, Tas, E, Serra, M, Tarkkanen, M, Knuutila, S 2005, 'Gene amplifications in 
osteosarcoma: CGH microarray analysis', Genes, Chromosomes & Cancer, vol 42, no. 2, pp. 158-163. 
Aurikko, JP, Ruotolo, BT, Grossmann, JG, Moncrieffe, MC, Stephens, E, Leppänen, V, Robinson, CV, Saarma, M, Bradshaw, RA, 
Blundell, TL 2005, 'Characterization of symmetric complexes of nerve growth factor and the ectodomain of the pan-neurotrophin 
receptor, p75[sup NTR]', Journal of Biological Chemistry, vol 280, no. 39, pp. 33453 - 33460. 
Baluk, P, Tammela, T, Ator, E, Lyubynska, N, Achen, MG, Hicklin, DJ, Jeltsch, M, Petrova, T, Pytowski, B, Stacker, SA, Ylä-Herttuala, 
S, Jackson, DG, Alitalo, K, McDonald, DM 2005, 'Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway 
inflammation', Journal of Clinical Investigation, vol 115, no. 2, pp. 247-257. 
Band, AM, Kuismanen, E 2005, 'Localization of plasma membrane t-SNAREs syntaxin 2 and 3 in intracellular compartments',  BMC Cell 
Biology, vol 6, pp. -. 
Bhardwaj, S, Roy, H, Kärpänen, T, Hi, Y, Jauhiainen, S, Hedman, M, Alitalo, K, Ylä-Herttuala, S 2005, 'Periadventitial angiopoietin-1 
gene transfer induces angiogenesis in rabbit carotid arteries', Gene Therapy (Basingstoke). 
Blay, J, Bonvalot, S, Casali, P, Choi, H, Debiec-Rychter, M, Dei Tos, AP, Emile, J, Gronchi, A, Hogendoorn, P, Joensuu, H, Le Cesne, 
A, McClure, J, Maurel, J, Nupponen, N, Ray-Coquard, I, Reichardt, P, Sciot, R, Stroobants, S, van Glabbeke, M, van Oosterom, A, 
Demetri, GD 2005, 'Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus 
Conference of 20-21 March 2004, under the auspices of ESMO', Annals of Oncology, vol 16, no. 4, pp. 566-578. 
Bono, P, Cordero, E, Johnson, K, Borowsky, M, Ramesh, V, Jacks, T, Hynes, RO  2005, 'Layilin, a cell surface hyaluronan receptor, 
interacts with merlin and radixin', Experimental Cell Research, vol 308, no. 1, pp. 177-187. 
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A2 Review in scientific journal 
2005 
Heinonen, M, Ristimäki, A 2005, 'Koksibit ja syövän ehkäisy ja hoito: voidaanko koksibeilla tehtäviä kliinisiä syöpätutkimuksia jatkaa?',  
Duodecim, vol 121, no. 9, pp. 929-931. 
Nykanen, AI, Pajusola, K, Keranen, M, Alitalo, K, Koskinen, PK, Lemstrom, KB 2005, 'Common anti-inflammatory and diverse smooth 
muscle cell effects of AAV-mediated angiopoietin-1 and-2 expression in rat cardiac allografts',  Journal of Heart and Lung 
Transplantation, vol 24, pp. S104-S104. 
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2006 
Brindle, NPJ, Saharinen, P, Alitalo, K 2006, 'Signaling and functions of angiopoietin-1 in vascular protection', Circulation Research, vol 
98, pp. 1014-1023. 
Hautaniemi, S, Vallenius, T, Mäkelä, T 2006, 'Systeemibiologia syöpätutkimuksessa: [katsaus]', Duodecim, vol 122, pp. 2484-2490. 
Järviluoma, A, Ojala, P 2006, 'Cell signaling pathways engaged by KSHV: [review]', Biochimica et Biophysica Acta. Reviews on 
Cancer, vol 1766, pp. 140-158. 
Tammela, T, Alitalo, K 2006, 'Yet another function for hepatocyte growth factor', Blood, vol 107, pp. 3424-3425. 
2007 
Heloterä, H, Alitalo, K 2007, 'The VEGF family, the inside story', Cell, vol 130, no. 4, pp. 591-592. 
Sarek, G, Ojala, P 2007, 'p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral 
lymphomas', Cell Cycle, vol 6, no. 18, pp. 2205-2209. 
2008 
Keski-Oja, J, Hyytiainen, M, Vehvilainen, P, Tatti, O, Kantola, AK, Lehti, K, von Melchner, H, Koli, K 2008, 'LATENT TGF-BETA 
BINDING PROTEINS (LTBPS) IN TARGETING TGF-BETA ACTION', Anticancer Research, vol 28, pp. 3345-3346. 
Koli, K, Myllärniemi, M, Keski-Oja, J, Kinnula, VL 2008, 'Transforming growth factor-[beta] activation in the lung: focus on fibrosis and 
reactive oxygen species', Antioxidants & Redox Signaling, vol 10, no. 2, pp. 333-342. 
2009 
Augustin, HG, Koh, GY, Thurston, G, Alitalo, K 2009, 'Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie 
system', Nature Reviews. Molecular Cell Biology, vol 10, pp. 165-177. 
Correia, M, Machado, JC, Ristimäki, A 2009, 'Basic aspects of gastric cancer', Helicobacter (Oxford), vol 14, no. suppl. 1, pp. 36-40. 
Mäkitie, A, Monni, O 2009, 'Molecular profiling of laryngeal cancer', Expert Review of Anticancer Therapy, vol 9, no. 9, pp. 1251-
1260. 
2010 
Bono, P, Joensuu, H 2010, 'Rintasyövän uudet täsmälääkehoidot', Duodecim, vol 126, no. 10, pp. 1205–1215. 
Kuznetsov, S, Chang , S, Sharan, S 2010, 'Functional analysis of human BRCA2 variants using a mouse embryonic stem cell-based 
assay.', Methods in molecular biology., vol 653, pp. 259-280. 
Resende, C, Ristimaki, A, Machado, JC 2010, 'Genetic and Epigenetic Alteration in Gastric Carcinogenesis',  Helicobacter (Oxford), vol 
15, no. Suppl. 1, pp. 34-39. 
Ristamäki, R, Salminen, P, Kokkola, AJ, Ristimäki, A 2010, 'Mahasyövän muuttuva ennuste ja hoito', Duodecim, vol 126, no. 20, pp. 
2363-2371. 
Tammela, T, Alitalo, K 2010, 'Lymphangiogenesis: Molecular Mechanisms and Future Promise',  Cell, vol 140, no. 4, pp. 460-476. 
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa, C, McGale, P, Taylor, C, Wang, Y, Clarke, M, Davies, C, Peto, R, 
Bijker, N, Solin, L, Darby, S, Joensuu, H 2010, 'Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the 
breast', Journal of the National Cancer Institute. Monographs, vol 2010, no. 41, pp. 162-177. 
A3 Contribution to book/other compilations (refereed) 
2007 
Joensuu, H, Leidenius, M, Huovinen, R, Smitten, KV, Blomqvist, C 2007, 'Rintasyöpä', Syöpätaudit, Duodecim, Helsinki, pp. 484-508. 
Mäkinen, T, Alitalo, K 2007, 'Lymphangiogenesis in development and disease', Vascular development, Novartis Foundation 
symposium, vol. 283, John Wiley & Sons, Hoboken, NJ. 
Stacker, SA, Farnsworth, RH, Karnezis, T, Shayan, R, Smith, DP, Paavonen, K, Davydova, N, Caesar, C, Inder, R, Baldwin, ME, 
McColl, BK, Roufail, S, Williams, RA, Hughes, RA, Alitalo, K, Achen, MG 2007, 'Molecular pathways for lymphangiogenesis and their 
role in human disease', Decoding the genomic control of immune reactions, Novartis Foundation symposium, vol. 281, John 
Wiley & Sons, Hoboken, NJ. 
2008 
Hyytiäinen, M, Koli, K, Keski-Oja, J 2008, 'Biological functions of latent TFG-[beta]-binding proteins and activation of TGF-[beta]', in 
EBSBJ (ed.), Transforming growth factor-[beta] in cancer therapy Volume I, Basic and clinical biology, Cancer drug discovery 
and development, Humana Press, c, Totowa, N.J, pp. 57-75. 
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Laakkonen, P, Zhang, L, Ruoslahti, E 2008, 'Peptide targeting of tumor lymph vessels', Annals of the New York Academy of 
Sciences. The Lymphatic Continuum Revisited., vol. 1131, Wiley, pp. 37-43. 
Moore, HM, Laiho, M 2008, 'Välkettä syvyyksistä - kemian Nobelin palkinto vihreän fluoresoivan proteiinin keksijöille',  Duodecim, 
Duodecim. 
2009 
Keski-Oja, J 2009, 'Transforming growth factor beta', in MS( (ed.), Encyclopedia of cancer, Springer, Berlin, pp. 3033-3037. 
Monni, O, Hautaniemi, S 2009, 'Bioinformatics of gene expression and copy number data integration',  Statistics and Informatics in 
Molecular Cancer Research, Oxford Scholarship Online Monographs, pp. 78-102. 
A4 Article in conference publication (refereed) 
2005 
Sano, M, Rossi, DJ, Mäkelä, TP, Kralli, A, Schneider, MD 2005, Menage-a-trois 1 (MAT1) is essential for the function of PPARgamma 
coactivator-1alpha (PGC-1alpha) in cardiac metabolism,, Circulation (Baltimore) 112 17 LIPPINCOTT WILLIAMS & WILKINS. 
2006 
Biberfeld, P, Pyakurel, P, Pak, F, Ojala, P, Mwakigonja, AR, Kaaya, EE, Castanos-Velez, E 2006, Kaposi (KS) pathogenesis: cell origin, 
HHV-8 permissiveness, proliferation, genomic instability,, Paper presented at 2006 International Meeting of The Institute of Human 
Virology, Baltimore, United States. 17. - 21. November, 2006. Retrovirology 3 BioMed Central. 
Joensuu, H 2006, 'GIST, menestystarina', in Sarkoomat, pp. 22-27. 
2007 
Karhemo, PR, Syrjakari, H, Kivinen, P, Valmu, L, Lundin, J, Joensuu, H, Laiho, M, Bono, P, Laakkonen, P 2007, Proteomic profiling of 
invasive cancer cells reveals a novel prognostic marker for human breast cancer,, EJC supplements 5. 
Sihto, H, Puputti, M, Heikkila, R, Lehtimaki, T, Holli, K, Kataja, V, Turpeenniemi-Hujanen, T, Isola, J, Lundin, J, Joensuu, H 2007, Breast 
cancer detection in mammography screening has independent influence on survival when cancer size and biological subtype are 
accounted for,, EJC supplements 5. 
2008 
Krebs, R, Tikkanen, JM, Nykanen, AL, Alitalo, K, Ylä-Herttuala, S, Koskinen, PK, Lemström, KB 2008, Role of vascular endothelial 
growth factor-C in experimental obliterative airway disease,, Journal of Heart and Lung Transplantation 27 ELSEVIER INC.. 
Ristolainen, H, Kuronen, A, Nordlund, K, Fujikane, M, Nowak, R 2008, 'Studies of the Elastic Properties of Amorphous SiO2 Nanoballs 
by Molecular Dynamics Simulations', in Symposium EE: Nano- and Microscale Materials: Mechanical Properties and Behavior 
under Extreme Environments. 
2009 
Chernenko, A, Reinman, M, Karhemo, PR, Goodison, S, Takkinen, K, Laakkonen, P 2009, Identification of novel cancer-associated 
molecules,, FEBS Journal 276 WILEY-BLACKWELL PUBLISHING LTD.. 
Konsti, J, Ahonen, T, Lundin, M, Joensuu, H, Pietikainen, M, Lundin, J 2009, Texture classifiers for breast cancer outcome prediction,, 
Virchows Archiv 455 SPRINGER. 
2010 
Kankaanranta, L, Saarilahti, K, Koivunoro, H, Seppälä, T, Kotiluoto, P, Auterinen, I, Savolainen, S, Joensuu, H  2010, 'Boron Neutron 
Capture Therapy (BNCT) in the Treatment of Recurred, Irradiated and Inoperable Meningioma', in New Challenges in NEUTRON 
CAPTURE THERAPY 2010 : Proceedings of 14th International Congress on Neutron Capture Therapy , pp. 539. 
Raivio, N, Tiraboschi, E, Saarikoski, ST, Castren, E, Kilanmaa, K 2010, THE EXPRESSION PROFILE OF BRAIN-DERIVED 
NEUROTROPHIC FACTOR IN THE RAT BRAIN AFTER ACUTE ETHANOL EXPOSURE,, Alcoholism: Clinical and Experimental 
Research 34 8 WILEY-BLACKWELL PUBLISHING, INC.. 
B1 Unrefereed journal article 
2005 
Eichmann, A, Mäkinen, T, Alitalo, K 2005, 'Neural guidance molecules regulate vascular remodeling and vessel navigation: [review]', 
Genes & Development, vol 19, no. 9, pp. 1013-1021. 
Oliver, G, Alitalo, K 2005, 'The lymphatic vasculature: recent progress and paradigms : [review]',  Annual Review of Cell and 
Developmental Biology, vol 21, pp. 17.804. 
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Tammela, T, Enholm, B, Alitalo, K, Paavonen, K 2005, 'The biology of vascular endothelial growth factors: [review]', Cardiovascular 
Research, vol 65, no. 13, pp. 550-563. 
Tammela, T, Petrova, T, Alitalo, K 2005, 'Molecular lymphangiogenesis: new players : [review]', Trends in Cell Biology, vol 15, no. 8, 
pp. 434-441. 
Wickström, SA, Keski-Oja, J 2005, 'Verisuonten tyvikalvojen pilkkoutumistuotteet: syövän kasvun estäjät?', Duodecim, vol 121, no. 17, 
pp. 1829-1837. 
2006 
Bono, P, Joensuu, H 2006, 'Angiogeneesin esto syövän hoidossa - ei enää pelkkiä lupauksia',  Duodecim, vol 122, no. 9, pp. 1037-
1044. 
Joensuu, H, Reichardt, P 2006, 'Imatinib and altered bone and mineral metabolism: [to the editor, correspondence]', New England 
Journal of Medicine, vol 355, no. 6, pp. 628. 
Joensuu, H, Bono, P 2006, 'Trastuzumab treatment in breast cancer: [correspondence, authors reply]', New England Journal of 
Medicine, vol 354, no. 20, pp. 2186. 
Lehtonen, A, Ojala, P 2006, 'Herpesvirukset ja immuunijärjestelmä: virusperäisen syövän alkulähteillä : [katsaus]', Duodecim, vol 122, 
pp. 1759-1766. 
Patja, K, Jousilahti, PJ, Hu, G, Vallenius, TK, Qiao, Q, Tuomilehto, J 2006, 'Tobacco smoke, systemic inflammation and the risk of type 
2 diabetes', Journal of Internal Medicine, vol 259, pp. 333. 
2007 
Bono, P 2007, 'Uutta toivoa levinneen munuaissyövän hoitoon: [pääkirjoitus]', Suomen lääkärilehti , vol 62, no. 1/2, pp. 27. 
Bono, P, Hietanen, P 2007, 'Rintasyövän vasta-ainehoidot - lupaava lisä yksilölliseen hoitoon: [pääkirjoitus]', Suomen lääkärilehti , vol 
62, no. 20/21, pp. 2027-2028. 
Kiviharju-af Hällström, TM, Jäämaa, S, Mönkkönen, M, Peltonen, K, Andersson, LC, Medema, RH, Peehl, DM, Laiho, M 2007, 
'Eturauhassyöpäalttiuden taustalla DNA-vauriovasteen puuttuminen: [Proc Natl Acad Sci USA in press]', Duodecim, vol 123, no. 9, pp. 
1019-1020. 
Laiho, M, Saksela, E 2007, 'Perimän vauriot, vanheneminen ja syöpä - erottamaton kolmikko: [pääkirjoitus]', Duodecim, vol 123, no. 13, 
pp. 1535-1536. 
Ristimäki, A 2007, 'Stamcellshypotesen och bröstcancer', Finska Läkaresällskapets Handlingar, vol 167, no. 2, pp. 74-77. 
Sarek, G, Kurki, S, Enbäck, J, Iotzova, G, Haas, J, Laakkonen, PM, Laiho, M, Ojala, PM 2007, 'p53-kasvurajoitereitin aktivaatio - uusi 
mahdollisuus virusperäisen lymfooman hoitoon: [J Clin Invest in press]', Duodecim, vol 123, no. 8, pp. 869-870. 
2008 
Katajisto, P, Vaahtomeri, K, Ekman, N, Ventelä, E, Ristimäki, A, Bardeesy, N, Feil, R, DePinho, R, Mäkelä, T  2008, 'Mutaatiot 
kasvaimen tukisoluissa polyyppien aiheuttajina: [referaatti Nature Genetics -lehden artikkelista]', Duodecim, vol 124, pp. 600-601. 
Lauttia, S, Palm, J, Rossi, D, Kaskenpää, N, Rajantie, I, Ylä-Herttuala, S, Alitalo, K, Weissman, I, Salven, P  2008, 'Aikuisen luuytimen 
kantasoluilla ei roolia verisuonten endoteelin uudismuodostuksessa ja kiinteiden kasvaimien kehittymisessä: [referaatti Proc Natl Acad 
Sci -lehden artikkelista]', Duodecim, vol 124, pp. 1083. 
Salven, P, Lauttia, S, Rossi, D, Ylä-Herttuala, S, Alitalo, K, Weissman, I 2008, 'Reply to Kerbel et al.: EPCs are again claimed to be 
essential in yet other models despite the irreproducibility of the original experiments introducing them: letter', Proceedings of the 
National Academy of Sciences of the United States of America, vol 105, no. 34, pp. E55. 
Syrjäkari, H, Laiho, M 2008, 'Välkettä syvyyksistä: kemian Nobelin palkinto vihreän fluorisoivan proteiinin keksijöille',  Duodecim, vol 
124, no. 22, pp. 2599-22601. 
2009 
Aebersold, R, Kallioniemi, O, Zupan, B 2009, 'Report on EU-USA workshop: how systems biology can advance cancer research (27 
October 2008)', Molecular oncology., vol 3, no. 1, pp. 9-17. 
Chaturvedi, AK, Kleinerman, RA, Hildesheim, A, Gilbert, ES, Storm, H, Lynch, CF, Hall, P, Langmark, F, Pukkala, E, Kaijser, M, 
Andersson, M, Fossa, SD, Joensuu, H, Travis, LB, Engels, EA 2009, 'Reply to P.A. Leppäluoto', Journal of Clinical Oncology, vol 27, 
no. 18, pp. 3066-3067. 
Joensuu, H 2009, 'Predicting recurrence-free survival after surgery for GIST', Lancet Oncology, vol 10, no. 11, pp. 1025. 
2010 
D'Amico, G, Alitalo, K 2010, 'Inside bloody lymphatics', Blood, vol 116, no. 4, pp. 512-513. 
Immonen, T, Salven, P 2010, 'Translaationaalisen lääketieteen maistereita Meilahdesta', Duodecim, vol 126, no. 6, pp. 596-597. 
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Joensuu, H, Bono, P, Kellokumpu-Lehtinen, P 2010, 'Two Important Determinants May Play a Role in the Success of the FinHer Trial - 
Reply to M. Isik et al', Journal of Clinical Oncology, vol 28, pp. 335-336. 
Mäkelä, T 2010, 'VIRKISTYSTÄ SYÖVÄN LÄÄKEKEHITYKSEN ALKULÄHTEILTÄ: METABOLINEN MUUTOS', Dosis, vol 26, no. 2, 
pp. 64-67. 
Pesonen, S, Helin, H, Nokisalmi, P, Escutenaire, S, Ribacka, C, Särkioja, M, Cerullo, V, Guse, K, Bauerschmitz, G, Laasonen, L, 
Kantola, T, Ristimäki, A, Rajecki, M, Oksanen, M, Haavisto, E, Kanerva, A, Joensuu, T, Hemminki, A 2010, 'Oncolytic adenovirus 
treatment of a patient with refractory neuroblastoma', Acta Oncologica, vol 49, pp. 117-119. 
Ristimäki, A 2010, 'Tumor suppressor effect of the microRNA miR-519 is mediated via the mRNA-binding protein HuR',  Cell Cycle, vol 
9, no. 7, pp. 1234-1234. 
B2 Contribution to book/other compilations (non-refereed) 
2008 
Band, A, Laiho, M 2008, 'Proteasome in the control of TGF-ß signaling during development and cancer', in SB Jakowlew (ed.) , 
Transforming Growth Factor-Beta in Cancer Therapy, Volume I, Humana Press, pp. 243-257. 
Saharinen, PI, Eklund, L, Alitalo, K 2008, 'Angiopoietins and the Tie receptors.', in W Figg, J Folkman (eds), Angiogenesis: An 
integrative approach from science to medicine, Springer. 
2009 
Heckman, CA, Holopainen, TT, Alitalo, K 2009, 'Molecular Targeting of Lymphangiogenesis and Tumor Metastasis', in L Stanley (ed.), 
From Local Invasion to Metastatic Cancer , Humana Press, pp. 283-295. 
Stacker, S, Achen, M, Haiko, P, Alitalo, K 2009, 'Lymphangiogenesis in Health and Disease – An Overview', in SA Stacker, MG Achen 
(eds), Lymphangiogenesis in Cancer Metastasis, Springer. 
B3 Unrefereed article in conference proceedings 
2006 
Dransfield, D, Laakkonen, P, Jussila, M, Arulanandam, A, Huang, L, Devy, L, Chen, J, Chang, Q, Pazmany, C, Rookey, K, 
Viswanathan, M, Mullberg, J, Schaus, J, Schoonbroodt, S, Steukers, M, Ladner, R, Wood, C, Alitalo, K 2006, 'Targeting tie-1 inhibits the 
growth of tumor xenografts as a monotherapy and has increased activity in combination with a VEGF inhibitor', in  18th EORTC-NCI-
AACR Symposium on Molecular Targets and Cancer Therapeutics , pp. 34-34. 
2009 
Ristimäki, A 2009, 'Ruokatorven syövän ja mahasyövän syyt ja luonne', in Ruokatorven syöpä ja mahasyöpä: Syöpäsäätiön XXXVI 
Symposiumi 5.–6.2.2009, pp. 17-21 Focus Oncologiae, vol. 10. 
Salven, P 2009, Bone marrow derived progenitor cells in angiogenesis and tumor growth,, Paper presented at 2nd International 
Kloster Seeon Meeting “Cellular and Molecular Mechanisms of Tumor Progression and Metastasis", Kloster Seeon, Germany. 
19. - 22. September, 2009. Journal of Vascular Research 46 S./KARGER AG. 
2010 
Laiho, M, Jäämaa, SS, af Hällström, TM, Sankila, A, Rantanen, V, Zhang, Z, Yang, Z, De Marzo, AM, Ruutu, M, Andersson, LC  2010, 
DNA Damage Recognition via Activated ATM Pathway in Non-proliferating Human Prostate Tissue: Proceedings of the 52nd Annual 
ASTRO Meeting,, International Journal of Radiation: Oncology - Biology - Physics 78 3; suppl. 1 ELSEVIER INC.. 
C2 Edited book, compilation, conference proceeding or special issue of journal 
2007 
Joensuu, H, Aalberg, V, Tenhunen, M (eds) 2007, Syöpätaudit, 3. p edn, Duodecim, Helsinki. 
D1 Article in professional journal 
2006 
Koli, K, Myllärniemi, M, Vuorinen, K, Salmenkivi, K, Ryynänen, M, Kinnula, V, Keski-Oja, J 2006, 'Uusi mekanistinen näkökulma 
idiopaattiseen keuhkofibroosiin: BMP-4:n estäjän gremliinin voimakas indusoituminen: [referaatti Am J Pathol artikkelista]',  Duodecim, 
vol 122 (2006), no. 14, pp. 1713-1714. 
2007 
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Moore, HM, Latonen, LM 2007, 'Tumajyväset solujen stressitilanteissa', Solubiologi. 
2010 
Leidenius, MH, Joensuu, H 2010, 'Rintasyövästä paranee yhä useampi, mutta paraneeko myös elämänlaatu?',  Duodecim, vol 126, no. 
10, pp. 1195-6. 
D2 Article in professional hand or guide book or in a professional data system, or text book 
material 
2010 
Hukkanen, V, Seppänen, M, Lautenschlager, I, Ojala, P 2010, 'Herpesvirusten ryhmä', in K Hedman, T Heikkinen, P Huovinen, A 
Järvinen, S Meri, M Vaara (eds), Mikrobiologia, Kustannus Oy Duodecim, pp. 524-568. 
Vaheri, A, Ojala, P 2010, 'Virukset ja syöpä', in K Hedman et al. (ed.), Mikrobiologia. mikrobiologia, immunologia ja 
infektiosairaudet. kirja 1., Kustannus Oy Duodecim, Helsinki, pp. 689-697. 
E1 Popular article, newspaper article 
2008 
Alitalo, K, Otonkoski, TPJ 2008, 'Vieraskynä/Pääkirjoitus: Kantasolukeksintö mahdollistaa henkilökohtaiset soluvaraosat', Helsingin 
Sanomat. 
H1 Patents 
2005 
Alitalo, K, Eriksson, U, Achen, M, Cregory Renner, C, Stacker, S, Li, H, Laakkonen, PM 2005, Multivalent antibody materials and 
methods for VEGF/PDGF family of growth factors, 2005087812. 
2006 
Alitalo, K, Laakkonen, PM, Kubo, H, Sainio, K 2006, Tie Receptor And Tie Ligand Materials And Methods For Modulating Female 
Fertility, 2006002854. 
2007 
Laakkonen, PM, Porkka, K, Hoffman, JA, Ruoslahti, E 2007, Peptides that home to tumor lymphatic vasculature and methods of using 
same, 7671021. 
2008 
Laakkonen, PM, Bergers, G, Ruoslahti, E 2008, A tumor homing peptide with potential as a pharmaceutical for cancer treatment and 
imaging, 20085427. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Kari Alitalo ,  Olli-Pekka Kallioniemi ,  Tomi Mäkelä , Kaisa 
Irene Lehti ,  ,  Pipsa Ilona Saharinen ,  Päivi Ojala ,  Marikki Laiho , 
 Juha Klefström ,  Emmy Verschuren ,  Pirjo Maarit Laakkonen , 
 Ari Ristimäki ,  Jorma Keski-Oja ,  Heikki Joensuu ,  
Carina Holmberg-Still ,  Outi Monni ,  Petri Salven ,  Sergey Kuznetsov , 
 Katri Koli , ,  Tuomas Tammela ,  ,  
Gabriela Veronica D Amico Lago ,  Masahiro Yamamoto, Andrei Anisimov ,  Michael Jeltsch , 
,  Zoltan Wiener ,  Milla Riikka Kivelä ,  Veli-Matti Leppänen , 
 , Maija Wolf ,  Niklas Karl Ekman, Pekka Katajisto, Saara Ollila , 
 Tea Kaarina Vallenius ,  Thomas Örjan Westerling, Grzegorz Sarek , Taija Maria af 
Hällström ,  Arja Band ,  ,  Sirkku Talvikki Saarikoski ,  Topi 
Tervonen ,  Merja Annikki Särkioja , Antti Rivinoja ,  Johanna Lammi , 
Marko Timo Tapio Hyytiäinen ,  ,  Petri Bono ,  Geert Hamer 
,  Tatiana Lepikhova ,  Wei Zheng ,  Ville Hyvönen ,  Harri Juhani 
Nurmi ,  Hanna Heloterä ,  Pirita Maria Pekkonen ,  Tanja Talvikki Holopainen , 
 Georgia Zarkada , Maija-Elina Bry ,  Kalle Ojala ,  Henrik Edgren 
,  Sami Kalevi Kilpinen ,  Kaisa Laajanen ,  Katja Pirita Helenius , 
 Emilia Kuuluvainen ,  Ying Yang ,  Kari Vaahtomeri ,  Lina 
Viveca Udd ,  Eeva Sofia Ojanen ,  Nami Sugiyama ,  Pipsa Meller , 
Anita Lampinen ,  Fang Cheng ,  Päivi Järvinen ,  Sari Susanna Jäämaa , 
 ,  Karita Dolores Peltonen ,  Henna Maaria Moore ,  , 
Vilja Maria Eskelinen ,  Anni Irmeli Nieminen ,  Johanna Inkeri Partanen , 
 Elsa De Oliveira Marques , Jenni Salla Pauliina Lahtela ,  Anastasiya Chernenko , 
 Piia-Riitta Karhemo ,  Mira Marie Heinonen ,  Camilla Böckelman , 
Alexandra Thiel , Johanna Mrena, Olga Tatti ,  ,  Marika Johanna 
Waltari ,  Harri Sihto ,  Marjut Puputti ,  Susanna Lauttia ,  Olli 
Matilainen ,  Henna Kristiina Heinonen ,  Heikki Ristolainen , Jing Wei , 
 Anna Kantola ,   
Activity type 
Supervisor or co-supervisor of doctoral thesis 60 
Prizes and awards 27 
Editor of research journal 16 
Peer review of manuscripts 64 
Assessment of candidates for academic posts 14 
Membership or other role in review committee 27 
Membership or other role in research network 13 
Membership or other role in national/international committee, council, board 103 
Membership or other role in public Finnish or international organization 18 
Membership or other role of body in private company/organisation 3 
Other tasks of an expert in private sector 2 
Participation in interview for written media 22 
Participation in radio programme 7 
Participation in TV programme 11 
Participation in interview for web based media 2 
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Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Kari Alitalo ,  
Supervision of PhD thesis/Tanja Holopainen, Kari Alitalo, 2004  … 
Supervision of PhD thesis/Hanna Heloterä, Kari Alitalo, 2006  … 
Supervision of PhD thesis/Terhi Kärpänen, Kari Alitalo, 2006 
Supervision of PhD thesis/Georigia Zarkada, Kari Alitalo, 2007  … 
Supervision of PhD thesis/Maria Wirzenius, Kari Alitalo, 2007 
Supervision of PhD thesis/Wei Zheng, Kari Alitalo, 2007  … 
Supervision of PhD thesis/Maija Bry, Kari Alitalo, 2008  … 
Supervision of PhD thesis/Marja Lohela, Kari Alitalo, 2008 
Supervision of PhD thesis/Paula Haiko, Kari Alitalo, 2008 
Supervision of PhD thesis/Tuomas Tammela, Kari Alitalo, 2008 
Supervision of PhD thesis/Camilla Norrmén, Kari Alitalo, 2009 
Supervision of PhD thesis/Harri Nurmi, Kari Alitalo, 2009  … 
Supervision of PhD thesis/Ville Hyvönen, Kari Alitalo, 2009  … 
Supervision of PhD thesis/Emilia Korhonen, Kari Alitalo, 2010  … 
Supervision of PhD thesis/Miia Taavitsainen, Kari Alitalo, 2010  … 
Tomi Mäkelä ,  
Supervision of PhD thesis/Helenius Katja, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Kovac Bianca, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Kuuluvainen Emilia, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Laajanen Kaisa, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Udd Lina, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Vaahtomeri Kari, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Ying Yang, Tomi Mäkelä, 2005  … 
Supervision of PhD thesis/Westerling, Thomas, Tomi Mäkelä, 2006 
Supervision of PhD thesis/Katajisto, Pekka, Tomi Mäkelä, 2008 
Kaisa Irene Lehti ,  ,  
Supervision of PhD thesis/Nami Sugiyama, Kaisa Irene Lehti, 2007  … 
Thesis review, Kaisa Irene Lehti, 2010, Finland 
Pipsa Ilona Saharinen ,  
Supervision of PhD thesis/Hanna Heloterä, Pipsa Ilona Saharinen, 2006  … 
Supervision of PhD thesis/Anita Lampinen, Pipsa Ilona Saharinen, 2010  … 
Päivi Ojala ,  
Doctoral thesis supervision, Päivi Ojala, 27.11.2007, Finland 
Doctoral thesis supervision, Päivi Ojala, 14.05.2010, Finland 
Marikki Laiho ,  
Mentoring: pre-doctoral, Marikki Laiho, 2000  … 
Mentoring: pre-doctoral, Marikki Laiho, 2001  … 
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Mentoring: pre-doctoral, Marikki Laiho, 2001  … 
Mentoring: pre-doctoral, Marikki Laiho, 2001  … 
Mentoring: pre-doctoral, Marikki Laiho, 2005  … 
Mentoring: pre-doctoral, Marikki Laiho, 2007  … 
Supervision of PhD thesis, Marikki Laiho, 2007 
Supervision of PhD thesis, Marikki Laiho, 2007 
Juha Klefström ,  
Doctoral thesis supervision / Nieminen, Juha Klefström, 2005  …, Finland 
Doctoral thesis supervision / Partanen, Juha Klefström, 2005  …, Finland 
Emmy Verschuren ,  
Mentoring a PhD student/Jenni Lahtela, Emmy Verschuren, 2009  … 
Mentoring a PhD student/Rita Cerejeira Matos, Emmy Verschuren, 2010  … 
Ari Ristimäki ,  
Supervision of doctoral thesis / Erkinheimo, Ari Ristimäki, 2005 
Supervision of doctoral thesis / Sivula, Ari Ristimäki, 2005 
Jorma Keski-Oja ,  
Supervision of PhD thesis/Olga Tatti, Jorma Keski-Oja, 2007  … 
Supervision of academic dissertation, Jorma Keski-Oja, 2007 
Supervision of PhD thesis/Yizhou Hu, Jorma Keski-Oja, 2008  … 
Supervision of PhD thesis/Irene Ylivinkka, Jorma Keski-Oja, 2009  … 
Supervision of academic dissertation, Jorma Keski-Oja, 2010 
Supervision of academic dissertation, Jorma Keski-Oja, 2010 
Petri Salven ,  
Doctoral thesis supervision / Lauttia, Petri Salven, 2007  …, Finland 
Doctoral thesis supervision / Fang, Petri Salven, 01.01.2010  …, Finland 
Sergey Kuznetsov ,  
Mentoring a PhD student Manuela Tumiati, Sergey Kuznetsov, 2009  … 
Mentoring a PhD student Yuexi Gu, Sergey Kuznetsov, 2009  … 
Katri Koli ,  ,  
Supervision of PhD thesis, Katri Koli, 2010 
Tuomas Tammela ,  ,  
Supervision of PhD thesis/Georigia Zarkada, Tuomas Tammela, 2007  … 
Supervision of PhD thesis/Harri Nurmi, Tuomas Tammela, 2009  … 
Milla Riikka Kivelä ,  
Supervision of PhD thesis/Miia Taavitsainen, Milla Riikka Kivelä, 2010  … 
Marko Timo Tapio Hyytiäinen ,  ,  
Supervision of PhD thesis/Yizhou Hu, Marko Timo Tapio Hyytiäinen, 2008  … 
Supervision of PhD thesis/Irene Ylivinkka, Marko Timo Tapio Hyytiäinen, 2009  … 
Prizes and awards 
Kari Alitalo ,  
Eric K Fernström Foundation's Nordic Prize, Kari Alitalo, 2005, Sweden 
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Pfizer Advances in Oncology Award, Kari Alitalo, 2005 
Louis-Jeantet Prize For Medicine, Kari Alitalo, 2006, Switzerland 
Suomen tiedeseuran jäsen, Kari Alitalo, 17.12.2007  …, Finland 
The InBev-Baillet Latour Health Prize, Kari Alitalo, 2009, Belgium 
Biomedicum Helsinki lecture and Medal 2010, Kari Alitalo, 19.10.2010 
The Anders Jahre Senior Medical Prize, Kari Alitalo, 08.10.2010, Norway 
The Michael O’Connor Award, Kari Alitalo, 2010, United States 
Olli-Pekka Kallioniemi ,  
AACR Team Science Award, Olli-Pekka Kallioniemi, 2008 
IFCC Abbott Award, Olli-Pekka Kallioniemi, 2008 
Tomi Mäkelä ,  
Membeship of the Finnish Academy of Science and Letters, Tomi Mäkelä, 2002  … 
Anders Jahre Young Investigator Award, Tomi Mäkelä, 01.01.2005, Norway 
Marikki Laiho ,  
Membeship of the Finnish Academy of Science and Letters, Marikki Laiho, 2008  … 
Pirjo Maarit Laakkonen ,  
The Best Poster Award, Pirjo Maarit Laakkonen, 2008 
Best presentation and poster award, Pirjo Maarit Laakkonen, 12.05.2009 
The Best Poster Award, Pirjo Maarit Laakkonen, 2009 
Jorma Keski-Oja ,  
Member, Finnish Science Academy (Finnish Acad. Sci &amp; Lett.), Jorma Keski-Oja, 2002  … 
Member, Societas scientiarum Fennica (Finnish Soc. Sci &amp; Lett.), Jorma Keski-Oja, 2008  …, Finland 
Heikki Joensuu ,  
Fellow of the European Academy of Cancer Sciences, Heikki Joensuu, 2010 
GIST Hall of Fame Award, Heikki Joensuu, 2010 
The Finnish Medical Foundation 50-year Anniversary Prize, Heikki Joensuu, 2010 
Tuomas Tammela ,  ,  
The Lymphatic Research Foundation Andrew Moisoff Young Investigator Award, Tuomas Tammela, 2006, United States 
The Faculty of Medicine Thesis of the Year Award, Tuomas Tammela, 2009 
The Werner Risau Prize, Tuomas Tammela, 2009, Germany 
Maija-Elina Bry ,  
Biomedicum Helsinki Foundation Young Scientist Award 2010, Maija-Elina Bry, 2010, Finland 
Emilia Kuuluvainen ,  
Helsingin Yliopiston Biotieteellisen Tiedekunnan Pro Gradu palkinto 2007, Emilia Kuuluvainen, 2007, Finland 
Ying Yang ,  
The1st prize for the poster, GSBM 2008 annual graduate student meeting, Ying Yang, 2008, Finland 
Editor of research journal 
Tomi Mäkelä ,  
Editorial Board Member/Duodecim, Tomi Mäkelä, 2001  … 
Biomedicine editor, Finnish Medical Journal Duodecim, Tomi Mäkelä, 01.01.2002  31.12.2009, Finland 
Editorial Board Member, "Scientific Reports", Nature Publishing Group, Tomi Mäkelä, 06.12.2010  …, United Kingdom 
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Marikki Laiho ,  
Annals of Medicine, Member of Editorial Board, Marikki Laiho, 2002  2007 
Ad Hoc Reviewer, several journals, Marikki Laiho, 2005  … 
Juha Klefström ,  
Academic editor for PLoS One, Juha Klefström, 2007 
Pirjo Maarit Laakkonen ,  
Annals Medicine, Pirjo Maarit Laakkonen, 01.01.2005  31.12.2005, Finland 
Ari Ristimäki ,  
Prostaglandins and Other Lipid Mediators., Ari Ristimäki, 2003  …, United States 
Heikki Joensuu ,  
Member of the Editorial Board/Acta Oncologica, Heikki Joensuu, 2004  … 
Member of the Editorial Board/Lancet Oncology, Heikki Joensuu, 2006  2009 
Member of the Editorial Board/The Open Clinical Cancer Journal, Heikki Joensuu, 2007  … 
Member of the Editorial Board/The Open General and Internal Medicine Journal, Heikki Joensuu, 2007  … 
Petri Salven ,  
Editorial board membership / Stem Cell Review Letters, Petri Salven, 2009  … 
Tea Kaarina Vallenius ,  
Duodecim, Tea Kaarina Vallenius, 01.01.2005  31.12.2005, Finland 
Esperimental Cell Research, Tea Kaarina Vallenius, 01.01.2005  31.12.2005, Finland 
Duodecim, Tea Kaarina Vallenius, 01.01.2006  31.12.2006 
Peer review of manuscripts 
Tomi Mäkelä ,  
Ad hoc referee: Science, Molecular Cell, Nature Genetics; EMBO Journal; Molecular Biology of the Cell; Oncogene; Drug Discovery 
Today; FEBS Letters; EMBO Reports; Human Molecular Genetics; PNAS, Journal of Cell Science; GUT; Gastroenterology, Tomi 
Mäkelä, 2005  … 
Kaisa Irene Lehti ,  ,  
Peer reviewer for Annal of Medicine, Kaisa Irene Lehti, 2005 
Peer reviewer for Journal of Biological Chemistry, Kaisa Irene Lehti, 2005 
Peer reviewer for EMBO Journal, Kaisa Irene Lehti, 2006 
Peer reviewer for International Journal of Cancer, Kaisa Irene Lehti, 2007 
Peer reviewer for Cell &amp; Tissue Research, Kaisa Irene Lehti, 2009 
Peer reviewer for International Journal of Cancer, Kaisa Irene Lehti, 2009 
Peer reviewer for Matrix Biology, Kaisa Irene Lehti, 2010 
Päivi Ojala ,  
Sodium butyrate induces apoptosis and cell cycle arrest in primary effusion lymphoma cells independently of oxidative stress and p21 
CIP1/WAF1 induction, Päivi Ojala, 05.08.2005, United States 
Expert Review of Anticancer Therapy, Päivi Ojala, 30.11.2006, United Kingdom 
A nuclear role for Kaposi’s sarcoma associated herpesvirus-encoded K13 protein in gene regulation, Päivi Ojala, 09.11.2007, United 
States 
Induction of paclitaxel resistance by the KSHV latent protein LANA2, Päivi Ojala, 12.04.2007, United States 
The chemokine receptor RDC1/CXCR7 in Kaposi’s sarcoma, Päivi Ojala, 22.09.2008, United States 
Cyclin-Dependent Kinase-like Function is Shared by the Beta- and Gamma- Subset of the Conserved Herpesvirus Protein Kinases., 
Päivi Ojala, 06.07.2009, United States 
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Pim-3 Protects against Cardiomyocyte Apoptosis in Anoxia/reoxygenation Injury via p38-mediated Signal Pathway, Päivi Ojala, 
07.05.2009, United States 
Plasmacytoid and myeloid dendritic cells efficiently mediate Kaposi's sarcoma-associated herpesvirus (KSHV) infection of primary B-
cells in vitro, Päivi Ojala, 24.09.2009, United States 
RAPID AND QUANTITATIVE ASSESSMENT OF KSHV LANA MEDIATED DNA REPLICATION, Päivi Ojala, 27.12.2010, Germany 
The lytic transcriptome of KSHV reveals extensive transcription of noncoding regions, including regions antisense to important genes, 
Päivi Ojala, 04.01.2010, United States 
Juha Klefström ,  
Peer review for Apoptosis, Juha Klefström, 2005  … 
Peer review for Duodecim, Juha Klefström, 2005  … 
Peer review for Journal of Cellular Biochemistry, Juha Klefström, 2005  … 
Peer review for Molecular and Cellular Biology, Juha Klefström, 2005  … 
Peer review for PLoS One, Juha Klefström, 2005  … 
Peer review for PNAS, Juha Klefström, 2005  … 
Peer review for Science, Juha Klefström, 2005  … 
Pirjo Maarit Laakkonen ,  
Annals Medicine, Pirjo Maarit Laakkonen, 01.01.2005  31.12.2005, Finland 
International Journal of Cancer, Pirjo Maarit Laakkonen, 2008 
Journal of Pathology, Pirjo Maarit Laakkonen, 2008 
Bioconjugate Chemistry, Pirjo Maarit Laakkonen, 2009 
FASEB Journal, Pirjo Maarit Laakkonen, 2009  2010 
Ari Ristimäki ,  
APMIS, Ari Ristimäki, 2009  2010 
Acta Obstetricia at Gyncologica Scandinavia, Ari Ristimäki, 2009 
BMC Cancer, Ari Ristimäki, 2009 
Carcinogenesis, Ari Ristimäki, 2009  2010 
European Journal of Cancer, Ari Ristimäki, 2009 
GUT, Ari Ristimäki, 2009  2010 
Human Genetics, Ari Ristimäki, 2009 
International Journal of Cancer, Ari Ristimäki, 2009 
Prostaglandins and Other Lipid Mediators, Ari Ristimäki, 2009  2010 
Histology and Histopathology, Ari Ristimäki, 2010 
Journal of Molecular Histology, Ari Ristimäki, 2010 
Heikki Joensuu ,  
Referee for Several Journals in 2010, Heikki Joensuu, 2010 
Carina Holmberg-Still ,  
Aging Cell, Carina Holmberg-Still, 2010 
PLoS One, Carina Holmberg-Still, 2010 
Petri Salven ,  
Peer review for American Journal of Pathology, Petri Salven, 2005  … 
Peer review for Arteriosclerosis, Thrombosis, and Vascular Biology, Petri Salven, 2005  … 
Peer review for Biochimica et Biophysica Acta (BBA - Reviews on Cancer), Petri Salven, 2005  … 
 
 
CANBIO/Alitalo 
 
 
7 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010 
 
 
Peer review for Blood, Petri Salven, 2005  … 
Peer review for British Journal of Cancer, Petri Salven, 2005  … 
Peer review for Critical Reviews in Oncology/Hematology, Petri Salven, 2005  … 
Peer review for Cytokine, Petri Salven, 2005  … 
Peer review for European Journal of Endocrinology, Petri Salven, 2005  … 
Peer review for European Journal of Haematology, Petri Salven, 2005  … 
Peer review for European Journal of Immunology, Petri Salven, 2005  … 
Peer review for International Journal of Cancer, Petri Salven, 2005  … 
Peer review for Investigative Ophthalmology &amp; Visual Science (IOVS), Petri Salven, 2005  … 
Peer review for Journal of Leukocyte Biology, Petri Salven, 2005  … 
Peer review for Journal of Thrombosis and Haemostasis, Petri Salven, 2005  … 
Peer review for Laboratory Investigation, Petri Salven, 2005  … 
Peer review for Leukemia, Petri Salven, 2005  … 
Peer review for Leukemia Research, Petri Salven, 2005  … 
Peer review for Oncology, Petri Salven, 2005  … 
Peer review for Thrombosis and Haemostasis, Petri Salven, 2005  … 
Katri Koli ,  ,  
Peer Review - several journals, Katri Koli, 2005  … 
Assessment of candidates for academic posts 
Tomi Mäkelä ,  
Docent review, 6 times 2005-2010 in Finnish universities, Tomi Mäkelä, 2005  2010, Falkland Islands 
EMBO Long-term Fellowship assessment: 2005, 2007, Tomi Mäkelä, 2005  2007 
ERC grant reviewer, Tomi Mäkelä, 10.2010  31.12.2013 
Päivi Ojala ,  
Conferment of title of Professor, Päivi Ojala, 2010, United Kingdom 
John D. and Catherine T. MacArthur Foundation Fellowship, Päivi Ojala, 18.08.2010, United States 
Juha Klefström ,  
Reviewer for docentship / Holmström, Juha Klefström, 2009  …, Finland 
Pirjo Maarit Laakkonen ,  
Assessment of candidates for academic posts, Pirjo Maarit Laakkonen, 2006, United States 
Evaluation for Docentship/Arja Kaitera, Pirjo Maarit Laakkonen, 2006 
Ari Ristimäki ,  
Evaluation for Associate Research Professorship, Ari Ristimäki, 2008  2009, United States 
Evaluation for Docentship / Kiuru, Ari Ristimäki, 2010, Finland 
Evaluation for Docentship / Sundström, Ari Ristimäki, 2010, Finland 
Jorma Keski-Oja ,  
Evaluator (Promotion to Full Professor), Jorma Keski-Oja, 03.2010 
Petri Salven ,  
Examiner for an Adjunct Professorship, Petri Salven, 2007, Finland 
Examiner for an Associate Professorship, Petri Salven, 2007, United States 
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Membership or other role in review committee 
Tomi Mäkelä ,  
Chairman, review committee for UH Medical Fund, Tomi Mäkelä, 2004  2005 
Instrumentarium Science Foundation Review Committee, Tomi Mäkelä, 2007  2030 
Dutch Digestive Foundation, Grant Reviewer 2008, Tomi Mäkelä, 2008 
Kaisa Irene Lehti ,  ,  
PhD committee member, Kaisa Irene Lehti, 2009  …, Finland 
Päivi Ojala ,  
Grant evaluation, Päivi Ojala, 12.01.2006, United Kingdom 
Grant reviews, Päivi Ojala, 2007  2010, Italy 
Grant reviews, Päivi Ojala, 12.06.2007, Lithuania 
Grant evaluation, Päivi Ojala, 02.08.2009, United Kingdom 
Grant reviewer, Päivi Ojala, 06.10.2009  08.10.2011, Finland 
Grant reviewer, Päivi Ojala, 03.12.2010, Finland 
Juha Klefström ,  
Reveier of scientific position / UCSF Comprehensive Cancer Center, Juha Klefström, 2005, United States 
Expert review for research program grants, Juha Klefström, 2007  2010, Norway 
Reviewer for scientific position in USCIS/Genentech Inc, Juha Klefström, 2008, United States 
Reviewer for ERC Advanced Grant, Juha Klefström, 2010 
Pirjo Maarit Laakkonen ,  
FWIS, L’oreal-Unesco Women in Science fellowship, Pirjo Maarit Laakkonen, 2008, Finland 
Reviewer of grants, Pirjo Maarit Laakkonen, 2008, Switzerland 
Reviewer of grants, Pirjo Maarit Laakkonen, 2009, Netherlands 
Reviewer of grants, Pirjo Maarit Laakkonen, 2009, Taiwan 
Reviewer of grants, Pirjo Maarit Laakkonen, 2009, Georgia 
FWIS, L’oreal-Unesco Women in Science fellowship, Pirjo Maarit Laakkonen, 2010, Finland 
Reviewer of grants, Pirjo Maarit Laakkonen, 2010, United Kingdom 
Heikki Joensuu ,  
Memeber of Assessment Board, Heikki Joensuu, 2007  … 
Carina Holmberg-Still ,  
Evaluation panel member, Carina Holmberg-Still, 2010 
Member of evaluation committee, Carina Holmberg-Still, 2010 
Petri Salven ,  
Doctoral committee member, Petri Salven, 2010  …, Finland 
Katri Koli ,  ,  
Reviewing of docent application, Katri Koli, 08.08.2006 
Reviewing of a grant application, Katri Koli, 2010 
Membership or other role in research network 
Tomi Mäkelä ,  
Coordinator, Biocentrum Helsinki Systems Biology Initiative, Tomi Mäkelä, 01.01.2005  01.01.2007 
ENFIN FP6 Network of Excellence, Tomi Mäkelä, 2006  2011 
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Vice Director, Center of Excellence in Translational Genome-Scale Biology, Tomi Mäkelä, 2006  2011 
Chair, Biocenter Finland Genome-Wide Methods Network, Tomi Mäkelä, 2007  2012 
Juha Klefström ,  
Chairman of the FinQB3 joint steering committee, Juha Klefström, 2007  2011 
Membership in Innovative Medicines Initiative - PREDECT, Juha Klefström, 2007  … 
Membership in Nordforsk network Chromatin, Transcription and Cancer, Juha Klefström, 2007  …, Sweden 
Member of Viral Gene Transfer and Cell Therapy Network, Juha Klefström, 2009  …, Finland 
Pirjo Maarit Laakkonen ,  
Management Coordinator, Pirjo Maarit Laakkonen, 01.05.2004  31.10.2009, Finland 
Carina Holmberg-Still ,  
Position of trust, Carina Holmberg-Still, 2010 
Sergey Kuznetsov ,  
LentiGEMM consortium, Emerging technologies network of Biocenter Finland 2010-2012, Sergey Kuznetsov, 01.01.2010  
31.12.2012, Finland 
Katri Koli ,  ,  
Member of American Society for Cell Biology, Katri Koli, 1999  … 
Member of Finnish Connective Tissue Society, Katri Koli, 2005  … 
Membership or other role in national/international committee, council, board 
Kari Alitalo ,  
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 1999  … 
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 2001  …, Italy 
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 2001  2005, Belgium 
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 2002  …, France 
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 2007  … 
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 2008  …, United States 
SCIENTIFIC ADVISORY BOARD MEMBER, Kari Alitalo, 2009  …, Finland 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
EDITORIAL BOARD MEMBERSHIP, Kari Alitalo, 2010 
Olli-Pekka Kallioniemi ,  
AACR, Olli-Pekka Kallioniemi, 2001  …, United States 
Human Protein Atlas Initiative, Olli-Pekka Kallioniemi, 2006  …, Sweden 
CREATE-Health, Olli-Pekka Kallioniemi, 2007  …, Sweden 
International Cancer Genome Sequencing Consortium, Olli-Pekka Kallioniemi, 2007  2008 
Biocenter Finland, Olli-Pekka Kallioniemi, 2008  …, Finland 
Biocentrum Helsinki, Board member, Olli-Pekka Kallioniemi, 2008  …, Finland 
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ESFRI, Olli-Pekka Kallioniemi, 2008  … 
HBGS, Olli-Pekka Kallioniemi, 2008  …, Finland 
Nordic EMBL, Olli-Pekka Kallioniemi, 2008  … 
Oslo Cancer Biomedicine Consortium, Olli-Pekka Kallioniemi, 2008  …, Norway 
University of Helsinki, Olli-Pekka Kallioniemi, 2008  …, Finland 
AACR, Olli-Pekka Kallioniemi, 2009  …, United States 
EBI-EMBL, Olli-Pekka Kallioniemi, 2009  … 
ERI-ICP, Olli-Pekka Kallioniemi, 2009  … 
European Academy of Cancer Societies, Olli-Pekka Kallioniemi, 2009  … 
WIN Consortium, Olli-Pekka Kallioniemi, 2009  … 
AACR, Olli-Pekka Kallioniemi, 2010  …, United States 
BF, Drug Discovery and Chemical Biology Initiative DDCB, Olli-Pekka Kallioniemi, 2010  …, Finland 
German Consortium for Translational Cancer Research, Olli-Pekka Kallioniemi, 2010  2011, Germany 
Tomi Mäkelä ,  
Steering Group member, MD PhD program, Faculty of Medicine, Tomi Mäkelä, 01.01.1996  31.12.2007, Finland 
Member, Biocentrum Helsinki, Tomi Mäkelä, 1998  31.12.2013, Finland 
Board Member, Meilahti Animal Facility, Tomi Mäkelä, 01.01.2001  31.12.2006, Finland 
Faculty of Medicine Postgraduate Education Committee, Tomi Mäkelä, 01.01.2003  31.12.2006, Finland 
SAB, Wihuri Research Foundation, Tomi Mäkelä, 01.01.2003  31.12.2011, Finland 
Scientific Advisory Board Member, Tomi Mäkelä, 2003  … 
Faculty of Medicine Research Council, Tomi Mäkelä, 01.01.2004  30.06.2009, Finland 
SAB, Finnish Cancer Institute, Tomi Mäkelä, 01.01.2004  31.12.2011, Finland 
Scientific Advisory Board Member, Tomi Mäkelä, 2004  … 
Chair, organizing committee, BioFinland 2005, Tomi Mäkelä, 26.04.2005  27.04.2005 
FinnSight2015 National Health Panel Member, Tomi Mäkelä, 01.01.2005  31.12.2005, Finland 
Steering Group, Masters Program in Bioinformatics, UH, Tomi Mäkelä, 01.01.2005  31.12.2011, Finland 
Center of Excellence in Translational Genome-Scale Biology, Tomi Mäkelä, 01.01.2006  31.12.2011, Finland 
Graduate School System Planning Group, HEA, Ireland, Tomi Mäkelä, 28.02.2006  21.09.2006, Ireland 
Initiator, LERU Biomedical Graduate Program, Tomi Mäkelä, 2006  2007, Finland 
Initiator, joint doctoral degree program, Karolinska-UH, Tomi Mäkelä, 2006  2007, Sweden 
Member of FinnSight2015 National Health Panel, Tomi Mäkelä, 2006 
Support Group for EU FP7 Health Area in Finland, Tomi Mäkelä, 2006  … 
UH Research Information System TUHAT: chair 06-08, coordination group 10-, Tomi Mäkelä, 2006  2011 
Chairman of the Board, Helsinki Biomedical Graduate School, Tomi Mäkelä, 2007  … 
Member of the steering committee for The Master's Degree Program in Translational Medicine, Tomi Mäkelä, 2008  2013 
Organizing committee, CNIO Cancer Conference: signalling upstream of mTOR, Tomi Mäkelä, 03.11.2008  05.11.2008, Spain 
TRANSMED Translational Masters Program, multiple roles, Tomi Mäkelä, 2008 
Chairman, JURE task force for national publication registry in Finland, Tomi Mäkelä, 2009  … 
Board member of the Bioinformatics Masters Program, Tomi Mäkelä, 2010 
Host, UH Honorary Doctor Robert A. Weinberg, Tomi Mäkelä, 03.06.2010 
Organizing committee, ENFIN-EMBRACE workshop, Tomi Mäkelä, 05.10.2010  06.10.2010, Finland 
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Päivi Ojala ,  
Center of Excellence in Translational Genome-Scale Biology, Päivi Ojala, 01.01.2006  31.12.2010, Finland 
EU-integrated project INCA, Päivi Ojala, 01.01.2006  31.12.2009 
Helsinki Biomedical Graduate School Board, Päivi Ojala, 03.04.2007  31.08.2008, Finland 
Helsinki Biomedical Graduate School Board, Päivi Ojala, 01.09.2008  …, Finland 
Marikki Laiho ,  
Graduate Program Memeber, Marikki Laiho, 2008  …, United States 
Graduate Program Memeber, Marikki Laiho, 2009  …, United States 
Juha Klefström ,  
Board of Gene Technology reviewer, Juha Klefström, 2007, Finland 
Pirjo Maarit Laakkonen ,  
Member of the Board, Pirjo Maarit Laakkonen, 2007  … 
Member of the Board, Pirjo Maarit Laakkonen, 01.01.2007, Finland 
Member of the Board, Pirjo Maarit Laakkonen, 01.01.2008  16.02.2011, Finland 
Member of the Organizing Committee, Pirjo Maarit Laakkonen, 2008, Finland 
Organizor, Pirjo Maarit Laakkonen, 2009, Finland 
Vice Member of the Board, Pirjo Maarit Laakkonen, 01.04.2010, Finland 
Ari Ristimäki ,  
Board member of Helsinki Biomedical Graduate School (HBGS), Ari Ristimäki, 1999  …, Finland 
European Helicobacter Study Group, Ari Ristimäki, 2008  … 
International Academy of Pathology (IAP) Finnish division, Ari Ristimäki, 2008  … 
Future trends committee, UEGF, Ari Ristimäki, 2010  … 
R&amp;D of HUSLAB molecular pathology, Ari Ristimäki, 2010  … 
Jorma Keski-Oja ,  
Board Member, Jorma Keski-Oja, 2000  2012 
Chair of the Grant evaluation board, Jorma Keski-Oja, 2008  … 
Chair of the M.D. &amp; Ph.D. program of the Faculty of Medicine, Jorma Keski-Oja, 2008  … 
Scientific board member, Jorma Keski-Oja, 2009  … 
Tieteellisen neuvoston jäsenyys, Jorma Keski-Oja, 12.03.2010  31.12.2012 
Heikki Joensuu ,  
Member of the Board, Heikki Joensuu, 2001  … 
Member of the Scientific Board, Heikki Joensuu, 2005  2007 
Member, Heikki Joensuu, 2010 
Member, Heikki Joensuu, 2010 
Member, Heikki Joensuu, 2010 
Member, Heikki Joensuu, 2010 
Member, Heikki Joensuu, 2010 
Memeber, Heikki Joensuu, 2010 
Scientific Committee Membership, Heikki Joensuu, 2010, Belgium 
Scientific Committee Membership, Heikki Joensuu, 2010, Belgium 
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Petri Salven ,  
Coordination committee member in Medical Technology Infrastructure Network, Petri Salven, 2007  …, Finland 
Expert member in Biomedicine and Molecular Biosciences (BMBS) Domain Committee, COST, Petri Salven, 2010  … 
Marko Timo Tapio Hyytiäinen ,  ,  
Member of the board; Finnish Connective Tissue Society, Marko Timo Tapio Hyytiäinen, 2008  … 
Petri Bono ,  
Membership in professional organization, Petri Bono, 2010  …, United States 
Membership in professional organization, Petri Bono, 2010  … 
Membership in professional organization, Petri Bono, 2010  … 
Membership in professional organization, Petri Bono, 2010  … 
Lina Viveca Udd ,  
Helsingin yliopiston tutkijalääkärilinjan johtoryhmä, Lina Viveca Udd, 31.08.2006  31.12.2006, Finland 
Piia-Riitta Karhemo ,  
FinnProt, Piia-Riitta Karhemo, 2008, Finland 
Membership or other role in public Finnish or international organization 
Tomi Mäkelä ,  
Finnish Medical Foundation, Member, Tomi Mäkelä, 01.01.1996  … 
Head, Meilahti Transgenic Unit, Tomi Mäkelä, 2001  2008 
Director, Helsinki Biomedical Graduate School, Tomi Mäkelä, 2002  2007 
Finnish Academy of Science and Letters, Member, Tomi Mäkelä, 01.01.2002  31.12.2011, Finland 
EMBO Member, Tomi Mäkelä, 16.02.2003  31.12.2030, Finland 
Director (acting), Biomedicum Helsinki, Tomi Mäkelä, 11.2004  11.2005 
Chairman of the Board, Finnish Medical Foundation, Tomi Mäkelä, 2005  2010 
Dean of Research, Faculty of Medicine, Tomi Mäkelä, 2007  2009 
Board Member, Biocenter Finland, Tomi Mäkelä, 01.01.2010  … 
Juha Klefström ,  
Founder and director of Biomedicum Virus Core Facility, Juha Klefström, 11.2002  …, Finland 
Research director of Biomedicum Functional Genomics Unit, Juha Klefström, 2006  … 
Jorma Keski-Oja ,  
Suomen Akatemian terveyden tutkimuksen toimikunnan jäsen, Jorma Keski-Oja, 01.01.2004  31.12.2006, Finland 
Heikki Joensuu ,  
Vice-chair, Heikki Joensuu, 2003  … 
Vice-chair, Heikki Joensuu, 2003  2010 
Expert member, Heikki Joensuu, 01.01.2009  … 
Member of the Board, Heikki Joensuu, 2009  2011 
Chair, Heikki Joensuu, 2010  … 
Outi Monni ,  
Research director of Biomedicum Functional Genomics Unit, Outi Monni, 2006  …, Finland 
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Membership or other role of body in private company/organisation 
Juha Klefström ,  
Chairman of the board in Biomedicum Genomics Ltd, Juha Klefström, 07.2007  2009, Finland 
Board membership in Biomedicum Genomics Ltd, Juha Klefström, 2009  … 
Jorma Keski-Oja ,  
Etelä-Pohjalainen osakunta: inspehtori, Jorma Keski-Oja, 01.01.2006  31.12.2006, Finland 
Other tasks of an expert in private sector 
Juha Klefström ,  
Coordinator of LentiGEMM Emerging Technology Platform, Juha Klefström, 2010  …, Finland 
Pirjo Maarit Laakkonen ,  
Coordinator of the Pharma meets Academia -event, Pirjo Maarit Laakkonen, 12.05.2009, Finland 
Participation in interview for written media 
Kari Alitalo ,  
Ei mikään yhden miehen show, Kari Alitalo, 2009, Finland 
Participation in interview/ Perspektiv: Infoblad om Helsingfors universitet, Kari Alitalo, 2009 
Olli-Pekka Kallioniemi ,  
New law to set up genetic bank, Olli-Pekka Kallioniemi, 04.2009, Finland 
Academy of Finland, Science Breakfast: Henkilökohtainen lääketiede avaa tietä yksilöllisille hoidoille, Olli-Pekka Kallioniemi, 
18.11.2010, Finland 
Maailman tutkituin syöpä, Olli-Pekka Kallioniemi, 15.10.2010, Finland 
Syövän hoitoa räätälöidyisti, Olli-Pekka Kallioniemi, 07.2010, Finland 
Tomi Mäkelä ,  
Participation in several interviews/Helsingin Sanomat, Tomi Mäkelä, 1996  2010 
Interview, Marita Räsänen, LÄÄKÄRIN AMMATTITAITO (book), Tomi Mäkelä, 15.06.2005 
Science Days Finland 2005: "Oncogenes", Tomi Mäkelä, 14.01.2005 
Science Days Finland 2005: professor on call, Tomi Mäkelä, 14.01.2005 
Science Days Finland 2007: Opportunities from Cancer Biology, Tomi Mäkelä, 10.01.2007 
Kiinnostus tutkijan työhön uhkaa hiipua, Tomi Mäkelä, 2009, Finland 
Juha Klefström ,  
Participation in a journal interview, Juha Klefström, 2007, Finland 
Participarion in interview for NordForsk Magasin, Juha Klefström, 2008 
Participation in interview for APU magazine, Juha Klefström, 2009, Finland 
Heikki Joensuu ,  
Participation in several interviews/Helsingin Sanomat, Heikki Joensuu, 22.11.2004  01.11.2010 
Syöpäpotilaat hyötyneet uudesta sädehoidosta, Heikki Joensuu, 02.12.2006 
Lääketutkimus ei enää houkuttele nuoria tutkijoita, Heikki Joensuu, 01.11.2010 
Tuomas Tammela ,  ,  
Participation in several interviews/Helsingin Sanomat, Tuomas Tammela, 2007  … 
Petri Bono ,  
Partcipation in interview, Petri Bono, 03.2008 
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Participation in interview, Petri Bono, 04.2009 
Maija-Elina Bry ,  
Participation in interview/ Perspektiv: Infoblad om Helsingfors universitet, Maija-Elina Bry, 2009 
Participation in radio programme 
Tomi Mäkelä ,  
Radiaattori: Transkriptiosta Nobelin palkinto/Sisko Loikkanen, Tomi Mäkelä, 11.10.2006 
Radiaattori: telomeraasista Nobel / Sisko Loikkanen, Tomi Mäkelä, 21.10.2010 
Petri Salven ,  
Participation in radio program / Tiedelinko, Petri Salven, 12.10.2007, Finland 
Participation in radio program / YLE Radio 1 Tiedeuutiset, Petri Salven, 23.04.2008, Finland 
Participation in radio program / Yle Radio 1 Reseptori, Petri Salven, 29.05.2008 
Participation in radio program / Yle Radio 1 Tiede, Petri Salven, 29.05.2008, Finland 
Tuomas Tammela ,  ,  
Radio Interview/Päivän peili, Tuomas Tammela, 25.06.2008 
Participation in TV programme 
Päivi Ojala ,  
Interview, Päivi Ojala, 21.03.2007, Finland 
Juha Klefström ,  
Participation in TV program / Yle Teema, Juha Klefström, 25.07.2006, Finland 
Participation in TV program on the Goodwill Gala Concert, Juha Klefström, 14.11.2009, Finland 
Heikki Joensuu ,  
FinXX tutkimus ja kapesitabiini syöpälääkkeenä, Heikki Joensuu, 23.09.2009 
Syövän hyvät hoitotulokset Suomessa, Heikki Joensuu, 07.05.2009, Sweden 
Kliinisen tutkimuksen ongelmat, Heikki Joensuu, 11.01.2010 
Rintasyövän hoitotulokset, Heikki Joensuu, 12.08.2010 
Uudet syöpähoidot, SOLD, FinHer ja FinXX, Heikki Joensuu, 27.01.2010 
Uudet syöpähoidot, SOLD, FinHer ja FinXX, Heikki Joensuu, 27.01.2010 
Petri Salven ,  
Participation in TV program / Prisma Studio, Petri Salven, 01.02.2006, Finland 
Petri Bono ,  
Aamu-tv, Petri Bono, 25.01.2010 
Participation in interview for web based media 
Tomi Mäkelä ,  
Tomi Mäkelä Helsingin biotekniikan instituutin johtoon, Tomi Mäkelä, 16.01.2009 
Annual Centre of Excellence seminar: Peer review easier in life sciences, Tomi Mäkelä, 14.12.2010 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Alitalo K 
Basic statistics 
Number of publications (P) 433 
Number of citations (TCS) 7,255 
Number of citations per publication (MCS)  17.08 
Percentage of uncited publications 16% 
Field-normalized number of citations per publication (MNCS)   1.86 
Field-normalized average journal impact (MNJS)   1.71 
Field-normalized proportion highly cited publications (top 10%)   2.40 
Internal coverage    .95 
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Performance (MNCS) by collaboration type 
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